- ¹Identification of ultra-rare genetic variants in Pediatric Acute Onset Neuropsychiatric Syndrome
- ²(PANS) by exome and whole genome sequencing
-
- 4 Rosario Trifiletti*¹, Herbert M. Lachman*², Olivia Manusama³, Deyou Zheng⁴, Alberto Spalice⁵,
- 5 Pietro Chiurazzi⁶, Allan Schornagel ⁷, Andreea M. Serban⁸, Rogier van Wijck⁸, Sigrid
- 6 Swagemakers⁸, Peter J. van der Spek⁸
-
- 8 Author Affiliations
- 9 ¹The PANDAS-PANS Institute, Ramsey, N.J., U.S.A
- 10 ²Department of Psychiatry and Behavioral Sciences, Department of Medicine, Department of
- ¹¹Genetics, Dominick P. Purpura Department of Neuroscience, Albert Einstein College of
- 12 Medicine. Bronx, New York, U.S.A
- ³Department of Immunology, Erasmus MC, Rotterdam, Netherlands
- 14 ⁴Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
- 15 ⁵Department of Pediatrics, Pediatric Neurology, Sapienza University of Rome
- 16 ^f Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore,
- 17 Dipartimento Scienze della Vita e Sanità Pubblica, Sezione di Medicina Genomica, and
- ¹⁸Dipartimento Scienze di Laboratorio e Infettivologiche, UOC Genetica Medica, Rome, Italy
- 19 ⁷GGZ-Delfland, and Kinderpraktijk Zoetermeer, Netherlands
- 20 ⁸ Department of Pathology and Clinical Bioinformatics, Erasmus MC, Rotterdam, Netherlands
-
- 22 $1,2$ These authors contributed equally to this work
-
- 24 ^{*}corresponding author: <u>Herb.Lachman@einsteinmed.org</u>
- 25 ² Present address: Department of Psychiatry and Behavioral Sciences, Albert Einstein College
- 26 Medicine. Bronx, New York, 10461, U.S.A
-

²⁸**Abstract**

29 Pediatric acute onset neuropsychiatric syndrome (PANS) is viewed as an

30 autoimmune/autoinflammatory condition characterized by the abrupt onset of severe 31 neurological and psychiatric symptoms, in particular obsessive-compulsive disorder (OCD), tics, 32 anxiety, mood swings, irritability, and restricted eating, often triggered by infections. However, 33 direct evidence of autoimmunity, infections, or a proinflammatory state is often lacking, and 34 there is no unifying pathogenic pathway. This could be due to underlying genetic heterogeneity, 35 which could lead to the development of PANS through different cellular and molecular 36 pathways. Unfortunately, little is known about the genetic basis of PANS. Consequently, we 37 carried out whole exome sequencing (WES) on a U.S. cohort of 386 cases who met diagnostic 38 criteria for PANS, including 133 family triads, and whole genome sequencing (WGS) on ten 39 cases from the European Union, who were selected for WGS because of severe PANS ⁴⁰symptoms. We focused on identifying potentially deleterious genetic variants that were either *de* ⁴¹*novo* or ultra-rare with a minor allele frequency (MAF) < 0.001. Candidate mutations were found ⁴²in 11 genes: *PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A*, *RAG1*, ⁴³*GABRG2*, and *SYNGAP1* in a total of 20 cases, which included two sets of siblings, and two or ⁴⁴more unrelated subjects with ultra-rare variants in *SGCE, NLRC4, RAG1,* and *SHANK3.* The ⁴⁵PANS candidate genes we identified separate into two broad functional categories. One group ⁴⁶regulates peripheral innate and adaptive immune responses (e.g., *PPM1D, CHK2, NLRC4,* ⁴⁷*RAG1, PLCG2*), some of which also influence microglia function. Another is expressed primarily ⁴⁸at neuronal synapses or directly modulates synaptic function (*SHANK3, SYNGAP1, GRIN2A,* ⁴⁹*GABRG2, CACNA1B, SGCE*). These neuronal PANS candidate genes are often mutated in 50 autism spectrum disorder, developmental disorders, and myoclonus-dystonia. In fact, eight out 51 of 20 cases in this study developed PANS superimposed on a preexisting neurodevelopmental 52 disorder. There is, however, clinical overlap between these two groups and some crossover

53 expression (e.g., some neuronal genes are expressed in immune cells and vice versa) that 54 diminishes the neuronal/immune dichotomy. Genes in both categories are also highly expressed 55 in the enteric nervous system, and in the choroid plexus and brain vasculature, suggesting they ⁵⁶might contribute to a breach in the blood-CSF barrier and blood-brain barrier (BBB) that would 57 permit the entry of autoantibodies, inflammatory cytokines, chemokines, prostaglandins, and 58 autoantibodies into the brain. Thus, PANS is a genetically heterogeneous condition that can 59 occur as a stand-alone neuropsychiatric condition or co-morbid with neurodevelopmental 60 disorders, with candidate genes functioning at several levels of the neuroinflammatory axis.

⁶²**Introduction**

⁶³The clinical entity known as PANS emerged from problems related to the diagnosis of PANDAS ⁶⁴(Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections). ⁶⁵In its original description, PANDAS was characterized by acute onset obsessive-compulsive 66 disorder (OCD) and tics following infection with group A beta-hemolytic streptococcus 67 (GABHS)^{1, 2}. The concept of PANS was introduced a decade later to expand the diagnosis to ⁶⁸include a multitude of acute-onset neuropsychiatric problems and exclude the requirement of 69 GABHS infection and tics (Table 1)³. PANDAS is now considered as a subgroup of PANS, 70 although some controversy remains. While some investigators have reported the presence of 71 autoantibodies against neuronal antigens and elevated levels of inflammatory cytokines in 72 PANS, these findings are inconsistent and the validity of the Cunningham panel of 5 biomarkers 73 used in diagnosing PANS has been supported in some studies and questioned in others $4-6$. 74 Imaging studies in some PANS cases show local inflammation in the thalamus, basal ganglia, 75 and amygdala, supporting a neuroinflammatory or autoimmune etiology. In addition, many 76 patients respond to immunomodulators, such as non-steroidal anti-inflammatory drugs ⁷⁷(NSAIDs), intravenous immunoglobulin (IVIG), corticosteroids, and more recently, the B-cell 78 inhibitor Rituximab^{4, 8}. However, this finding is controversial as some investigators have

79 expressed concerns about the dearth of large, well-controlled clinical trials $6, 7, 9$. Because of 80 these issues and the lack of consistent, objective biomarkers, many children remain 81 undiagnosed and undertreated, adversely affecting both patients and their families, and perhaps 82 contributing to disease chronicity. According to the Stanford PANS Clinic, the median Caregiver 83 Burden Inventory (CBI) during a 1st PANS flare is 37, which is higher than the CBI for those 84 caring for someone with Alzheimer disease and similar to that found in Rett syndrome 10 . 85 Although most children with PANS show significant improvement at follow-up, according to a 86 recently published longitudinal study, full remission was rare, and more than one-third were 87 classified as having a chronic course 11 . 88 One plausible explanation for the inconsistent findings related to the presence or 89 absence of autoantibodies and inflammatory markers, and the relationship to infectious 90 pathogens, is heterogeneity in the infectious diseases other than GABHS, such as *Mycoplasma* ⁹¹*pneumoniae, Borrelia burgdorferi* and influenza virus, that might act as autoimmune or 92 proinflammatory triggers 12 . Another possibility is that non-infectious environmental factors that 93 activate innate immune pathways (i.e. sterile or non-infectious inflammation), such as oxidative 94 stress, exposure to toxins, or emotional stress, could trigger an abnormal inflammatory 95 response in genetically susceptible children. Finally, heterogeneity in genetic risk factors that ⁹⁶cause dysregulation of peripheral immunity, or central neuronal/innate immune pathways could 97 be at play, all leading to a common clinical phenotype. In this model, some genetic subgroups 98 will express classic markers of inflammation or autoantibodies, but not others. However, gene 99 discovery in PANS that can test this model is still in its infancy. ¹⁰⁰Whole exome sequencing (WES) and whole genome sequencing (WGS) are gene

102 biologically powerful genetic factors underlying disease states. However, such studies have not 103 yet been reported in PANS. We now describe the discovery of ultra-rare variants in 11 genes in 104 20 PANS cases using WES and WGS technologies.

101 discovery tools used by researchers, and increasingly by clinicians, to identify ultra-rare,

105

¹⁰⁶**Subjects and Methods**

¹⁰⁷**Subjects.** The European subjects were identified through a call for patients with severe 108 symptoms from a PANS/PANDAS advocacy group called EXPAND after a teenage girl with 109 chronic PANS was found to have an ultra-rare variant in the *PPM1D* gene by WGS. EXPAND is 110 a European advocacy organization for families of children and adolescents with immune-¹¹¹mediated neuropsychiatric disorders. Parents, caretakers, or patients signed informed consents 112 approved by the Ethical Committee at Erasmus MC (MEC-2011-253 for control samples and 113 MEC-2021-0359 for PANS patients; IRB/ Human Subject Assurance number/Federal Wide ¹¹⁴Assurance, FWA00001336). Histories from this cohort were obtained by the participating 115 physicians and collated by one of the co-authors (O.M). 116 Cases from the U.S. were obtained from a large private practice run by one of the 117 authors (R.T) devoted to PANS (PANDAS/PANS Institute, Ramsey, NJ). 383 PANS cases and 118 263 controls that included 133 triads had WES carried out by Centogene (see below) (Rostock, 119 Germany). The subjects signed an informed consent by Centogene to which they agreed to 120 provide anonymized genetic information for research purposes. The corresponding author has 121 IRB approval from the Albert Einstein College of Medicine to obtain and analyze deidentified 122 data from human subjects (approval ID, 2000-014). Each case in the U.S. cohort was personally

123 treated by one physician (R.T) who obtained a detailed personal and family history.

¹²⁴To protect patient confidentiality, detailed histories are only available upon request to the 125 corresponding author. The consenting parents and participants have agreed to have the results 126 of this research work published.

127

¹²⁸**WGS and WES data analysis.** The EU cases were sequenced using DAB nanoball sequencing 129 for WGS and Illumina for WES. We implemented ANNOVAR, an efficient software tool that 130 utilizes up-to-date information to functionally annotate genetic variants and allele frequencies

131 detected in each patient's genome. In addition to gene-based annotation, ANNOVAR is used for 132 region-based annotations to identify variants in specific genomic regions, such as ultra-133 conserved regions across species (Vista database), predicted transcription factor binding sites ¹³⁴(Transfac), segmental duplication regions, genome wide association study (GWAS) hits, 135 database of genomic variants, DNAse I hypersensitivity sites, ENCODE 136 H3K4Me1/H3K4Me3/H3K27Ac/CTCF sites, ChIP-Seq peaks, RNA-Seq peaks, and other 137 annotations in genomic intervals. DNA nanoball sequencing has been applied for WGS to study 138 non-coding regions and in particular variants within the ultra-conserved regulatory regions. This 139 provided highly reliable variant lists that were compared with our selected variants and filtered 140 based on allele frequency in GNOMAD ClinVar (public NCBI repository derived data). Only 141 variants that occurred in patients and are never detected in 597 healthy elderly (Welderly) 142 sample genomes were considered 13 . DNA Nanoball sequencing protocol is detailed in the 143 classic paper by Drmanac et al 14 . The ultra-rare variant assessment was confirmed using 144 additional cohorts that have been sequenced by the Erasmus MC team headed by one of us ¹⁴⁵(P.S.).

146 The U.S. samples were sequenced by Centogene using double stranded DNA capture 147 baits against approximately 36.5 Mb of the human coding exome (targeting >98% of the coding 148 elements). RefSeq from the human genome build GRCh37/hg19) are used to enrich target 149 regions from fragmented genomic DNA with the Twist Human Core Exome Plus kit. The 150 generated library was sequenced on an Illumina platform to obtain at least 20x coverage depth 151 for >98% of the targeted bases. The investigation for relevant variants focused on coding exons 152 and flanking +/-20 intronic nucleotides of genes with a clear gene-phenotype evidence (based 153 on OMIM® information). The resulting variant call (VCF) file was then subjected to a custom 154 pipeline developed at the PANDAS/PANS Institute. For this study, we searched for variants with 155 all of the following properties: 1) minor allele frequency (MAF) of <0.001: 2) American College of 156 Medical Genetics Class 5 or 4 (i.e., "pathogenic" or "likely pathogenic"): 3) among a

157 PANDAS/PANS institute cohort of 383 cases and 263 controls variants that were never

158 observed, with rare exceptions noted, in controls.

¹⁶⁰**Network analysis.** Functional analysis was performed within Ingenuity Pathway Analysis (IPA) ¹⁶¹(QIAGEN Inc.). All candidate genes were imported in IPA to assess the pathways involved. Two 162 additional, unpublished, PANS candidate genes (*MTHC2* and *BID*) were added to the analysis. 163 Using the network tool within IPA, a connectivity network was constructed based on the 164 IPA/QIAGEN Knowledge Base. Both direct and indirect relationships were used to construct the 165 biological network.

¹⁶⁷**RNA expression analysis.** The gene expression profiles of the candidate genes were analyzed 168 using several datasets. First, we hypothesized that microglia might play a critical role in the ¹⁶⁹PANS phenotype especially after an inflammatory stimulus. Consequently, a subset of 159 170 autism and pediatric immune disorder genes was analyzed based on a public dataset 171 investigating the effect of LPS on murine microglia and macrophages (GSE102482)¹⁵. After 172 Robust Multichip Average normalization (RMA), a statistical analysis of microarray (SAM) was 173 performed between non-stimulated microglia and LPS-stimulated microglia within OmniViz 174 version 6.1.13.0 (Instem Scientific). The top 15 up-regulated and down-regulated genes were 175 selected for visualization and further analysis. 176 Next, we investigated the gene expression profiles of our 11 PANS-associated 177 candidates in peripheral blood mononuclear cells (PBMCs) under baseline conditions and after

178 infection as many patients develop PANS symptoms following infections. Given the rising 179 reporting of neuropsychiatric symptoms after COVID-19 infection, we used a recently published 180 single cell RNA-seq (sc-RNA-seq) COVID-19 dataset to investigate the gene expression profiles 181. ¹⁶. This database contains gene expression patterns in control samples (N=6) and hospitalized 182 severe COVID-19 patients $(N=7)$.

¹⁸³To investigate the expression of the candidate genes in normal human tissue we used 184 the Genotype-Tissue Expression (GTEx) dataset 17 . We used the GTEx Multi Gene Query 185 available on the GTEx portal to construct the RNA profiles in normal human tissue lineages. 186 Finally, as the GTEx portal uses bulk RNA-seq data, we wanted to further investigate the gene 187 expression profiles in more detail. Because neurological and psychiatric symptoms are cardinal 188 in PANS, we were particularly interested in scRNA-seq in brain tissue. scRNA-seq data is not 189 yet available for human brains, however, recently two datasets were published containing 190 scRNA-seq data for adolescent and fetal mouse brains^{18, 19}. All candidate genes were 191 investigated in both datasets on the Mouse Brain Atlas portal.

¹⁹³**Results**

¹⁹⁴We identified ultra-rare variants in 11 genes (*PPM1D, SGCE, PLCG2, NLRC4, CACNA1B,* ¹⁹⁵*SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1*) in 20 patients who met diagnostic 196 criteria for PANS as established by the PANS Consensus Conference 3 . The ultra-rare variants ¹⁹⁷and brief descriptions of the cases are shown on **Figure 1** and **Table 2**, respectively. In the ¹⁹⁸European cohort, two affected siblings (cases 1 and 2) were found with an ultra-rare missense 199 mutation in *PPM1D* (c.131C>G; p.S44W). They inherited the variant from an asymptomatic 200 parent who has a family history autoimmune disorders, a common scenario in PANS families 20 , 201 21 . S44W is a known single nucleotide variant (SNV), rs373862041, with a minor allele 202 frequency (MAF) of 0.000255, based on the TOPMed database of more than 125,000 samples 22 ²⁰³. The ultra-rare variant in *CACNA1B,* found in two affected siblings (cases 3 and 4), is a 48 bp 204 insert at the exon 2 splice donor site (c.390+1) that is predicted to disrupt splicing. It is part of a 205 set of multiallelic insertion variants, rs370237172, that has an overall MAF of 0.017. However, 206 the 48 bp insert is ultra-rare and has not been observed in control data sets. We have been 207 unable to genotype the parents. Interestingly, the same 48 bp insert was identified in a young 208 woman who has been incapacitated with chronic fatigue syndrome (myalgic encephalomyelitis)

209 and anorexia (unpublished observations). This insert shows a 100% hit with a human oral 210 metagenome assembly (unpublished results from ME/CFS project headed by Dr. Rogier 211 Louwen, Erasmus MC).

212 Known transmission from a parent in the European cohort was also found in cases 9 and

²¹³10 (*NLRC4*: c.772T>C; p.C258R; and *SGCE*: del150 Iso; c.450_452, respectively), which will be 214 discussed below. For the other ultra-rare variants, parental genotypes are not available. 215 Remarkably, in the U.S. cohort, different ultra-rare variants were found in two of the same genes 216 identified in the European cohort (*NLRC4* and *SGC2*), and another, *CHK2*, codes for a well-217 established PPM1D substrate 23 . A total of four different candidate variants were found in ²¹⁸*NLRC4*, the most for any PANS-associated gene. Ultra-rare variants were also found in ²¹⁹*SHANK3* and *RAG1* gene in three patients each. Case 17 has an ultra-rare variant in *SHANK3* ²²⁰(c.4622C>T, P1541L) and a nonsense mutation in *NLRC4* (c.928C>T, p.310X). 221 The finding of ultra-rare mutations in the same genes in unrelated individuals points to a 222 true association. 223 These 11 genes separate into two broad functional categories; those that affect 224 peripheral innate and adaptive immune pathways, and those that are expressed primarily in 225 cortical neurons, where they function as synaptic regulators. Some of the immune genes also 226 have significant effects on microglia, and the synaptic genes have all been implicated in other 227 neurological and neurodevelopmental disorders. In addition, several neuronal genes are 228 expressed in the choroid plexus and brain vasculature, suggesting they might contribute to a 229 breach in the blood-CSF barrier and blood-brain barrier (BBB) that accompanies inflammation 230 and infection. However, as described below, this dichotomy between immune and neuronal 231 candidate genes is an over-simplification.

²³³**PANS candidate genes that primarily function in the peripheral immune system**

²³⁴*PPM1D, CHK2, PLCG2, RAG1,* and *NLRC4* have well-established effects on peripheral innate 235 and adaptive immunity. *PPM1D* codes for a serine/threonine phosphatase that negatively 236 regulates p53 and other members of the DNA repair pathway. Somatic *PPM1D* gain of function 237 mutations act as tumor suppressor genes $24-26$. The most common are frameshift and nonsense 238 mutations in exons 5 and 6 that lead to the production of a truncated protein that has a 239 stabilizing effect on the retained catalytic portion. Germline exons 5 and 6 truncating mutations 240 are found in children with Jansen de Vries Syndrome (JdVS) $27-31$. JdVS is characterized by 241 intellectual and developmental disabilities (IDD), restricted eating, high pain threshold, ASD, and 242 psychiatric symptoms (primarily severe anxiety). Thus, there is some overlap in the clinical 243 features observed in PANS and JdVS (e.g., restricted eating, anxiety). However, IDD is nearly 244 universal in JdVS, while the two cases with the S44W variant excelled at school until the 245 development of PANS, which became chronic, leading to persistent neuropsychiatric problems 246 and academic regression. Most children with JdVS have a history of recurrent infections 27 . 247 However, no consistent immunological findings have been reported. PPM1D regulates T- and ²⁴⁸B-lymphocyte differentiation, and cytokine production, with *Ppm1d* deficient mice exhibiting a 249 proinflammatory state following an immune challenge, and an increase in macrophage 250 phagocytosis and autophagy $32-36$. PPM1D has also been found to inhibit intestinal inflammation 251 in inflammatory bowel disease and negatively regulates cytokine production in human 252 neutrophils during sepsis ³⁷. The proinflammatory state in *Ppm1d* null mice mimics that seen in 253 PANS patients, suggesting that S44W may induce an exaggerated inflammatory response 254 following an immune challenge through a loss-of-function effect on PPM1D catalytic activity in 255 immune cells. Alternatively, a proinflammatory state could occur through disruption of immune 256 responses caused by other regulatory proteins affected by S44W (see discussion). 257 Similar to *PPM1D*, *CHK2* also codes for a regulator of the DNA repair response by 258 phosphorylating p53 $^{23, 38}$. Germline loss of function mutations in the kinase domain are found in

several inherited cancer syndromes 39, 40 ²⁵⁹*.* The protein encoded by *CHK2* is expressed in T-cells

260 and regulates IL-2 expression 41 . The rare variant we identified, T410fsX14, is a truncating 261 mutation in the distal end of the kinase domain and is probably a loss-of-function mutation. 262 Chk2 inactivation in mouse B cells leads to decreased Ig hypermutation and Ig class switching 263 42 , conditions that can, along with a DNA repair defect, lead to immune dysregulation $43-45$. 264 Defective DNA repair could also underlie the effects of the S44W *PPM1D* variant on immune 265 function.

²⁶⁶The finding of an ultra-rare variant in *PPM1D* and in one of its principal targets, *CHK2,* 267 strongly supports the idea that these are indeed PANS-causing mutations.

²⁶⁸*PLCG2* is primarily expressed in B-cells, and gain-of-function mutations have been 269 found in patients with severe sterile inflammation, recurrent bacterial infections, autoimmune 270 disorders, and humoral immunodeficiency ⁴⁶⁻⁴⁹. The *PLCG2* Y206F variant maps to the EF hand 271 domain that binds calcium. Gain of function mutations in *PLCG2* cause autoinflammatory 272 disease through an increase in calcium influx upon B-cell activation 50 . However, the effect of 273 Y206F on calcium homeostasis awaits experimental validation.

²⁷⁴*NLRC4* codes for a component of the inflammasome, a cytosolic multiprotein complex 275 that assembles in response to exogenous or endogenous stressors, thereby playing a major 276 \cdot role in autoinflammatory diseases and macrophage activation syndrome $51-56$. NLRC4 also 277 regulates panoptosis, a recently identified inflammatory programmed cell death pathway, 57 and 278 Th17 cells in mice exposed to osmotic stress ⁵⁸.

279 A total of four patients with ultra-rare variants in *NLRC4* were found in our two cohorts ²⁸⁰(including patient 17 who also has a *SHANK3* variant). Two variants, c.772T>C (p.C258R) and 281 c.928C>T (p.R310X) map to the NACHT domain, which has intrinsic ATPase activity and 282 facilitates self-oligomerization 59 . Gain of function mutations in this region lead to severe 283 hyperinflammatory disorders 55 . Such mutations abrogate autoinhibition by the C-terminal 284 leucine rich region 60 , p.R310X would eliminate this region from the protein. The other two ultra-285 rare variants, c.2309T>C (p.M770T) and c.1799A>G (p.E600G), map to the leucine-rich repeat

286 region (LRR). Mutations in the LRR affecting the oligomerization interface were recently 287 described in two patients with early-onset macrophage activation syndrome 61 .

288 *RAG1* codes for recombination activating gene 1, which is involved in antibody and T-289 cell receptor V(D)J recombination. RAG1 deficiency leads to abnormalities in T- and B-cell 290 tolerance and immune dysregulation, leading to both an increased risk of infection and 291 autoimmune problems $62, 63$. Ultra-rare mutations were found in three patients, one of which, 292 c.256 257delAA causes a frameshift in exon 2 (p.K86VfsX33). This variant has previously been 293 reported in a heterozygous patient with adult-onset lymphopenia, and in a homozygous patient

294 with severe combined immunodeficiency (SCID) 64 .

295

²⁹⁶**PANS candidate genes that affect microglia function**

297 Several of the PANS candidate genes that affect the peripheral immune system also disrupt ²⁹⁸microglia function. For example, *Ppm1d* null mice exposed to a hypobaric hypoxic environment 299 showed an augmented release of inflammatory cytokines from activated microglia ⁶⁵. In ³⁰⁰microglia derived from iPSCs, PLCG2 expression was found to mediate cell survival, 301 phagocytosis, and processing of neuronal debris 66 . Finally, Nlrc4 regulates apoptotic and 302 pyroptotic microglial death following ischemic stroke $67, 68$, and astrogliosis and microgliosis in a 303 mouse model of neuroinflammation ⁶⁹.

³⁰⁴Additional support for an immune-related effect of a subgroup of PANS-associated 305 candidate genes on microglia function comes from our analysis of a gene expression dataset in 306 LPS-treated mice (GSE102482)¹⁵. We found that *Sgce* and *Plcg2* were the 2nd and 8th most 307 downregulated transcripts, and *Nlrc4* the 6th most upregulated transcript, in microglia derived 308 from control and LPS-treated mice upon an analysis of a subset of 148 autism and pediatric ³⁰⁹immune disorder genes (**Figure 2)**.

336 minimal verbal ability since early childhood. She developed the sudden onset of OCD and 337 aggression as a child that improved dramatically with IVIG, although the baseline ASD and poor 338 verbal ability did not improve.

339 Our finding of co-morbid ASD and PANS in the SHANK3 cases is similar to observations ³⁴⁰made by Bey et al., who identified *de novo SHANK3* variants in four girls with lifelong, stable 341 developmental delay (DD) who developed subacute, severe psychiatric symptoms resembling 342 PANS, that responded, with varying degrees of success, to immunotherapy ⁸⁰. Similarly, in an 343 analysis of 38 individuals with Phelan-McDermid Syndrome, acute regression triggered by 344 infections, changes in hormonal status, and stressful life events were commonly observed, 345 several of whom improved with IVIG 81 . ³⁴⁶These findings show that a subgroup of patients with *SHANK3*-associated ASD and

347 developmental disorders have an underlying susceptibility to develop acute onset 348 neuropsychiatric problems that have a neuroinflammatory component.

³⁴⁹Four other PANS-associated neuronal candidate genes we identified, *SYNGAP1,* ³⁵⁰*GRIN2A, GABRG2,* and *CACNA1B* mutations have also been found in ASD, epilepsy, and IDD ^{77, 82-86}. GRIN2A and SYNGAP1 bind to PSD-95. According to the SFARI database, *SYNGAP1* 352 has the ninth highest number of reports. It codes for a postsynaptic Ras GTPase activating 353 protein that regulates developing excitatory synaptic structure and function 87 . Case 8 has a 354 nonsense mutation at *SYNGAP1* codon 1179. Like the *SHANK3* cases, she was diagnosed with 355 ASD as a child, and developed acute onset OCD and food restrictions following a culture 356 positive streptococcus pharyngitis.

³⁵⁷*GRIN2A* codes for the glutamate ionotropic receptor NMDA type subunit 2A. Mutations 358 have been found in a variety of neurodevelopmental disorders including ASD, epilepsy, and 359 developmental disabilities $84, 88$. The ultra-rare variant found in case 6 maps to a conserved 360 region of the CTD domain, which is involved in mediating intracellular signaling 85 . The CTD 361 region interacts with the MAGUK (membrane-associated guanylate kinase) family of proteins

362 that bind to PSD-95 and function as important modulators of synaptic plasticity 89 . This subject 363 has a history of dyslexia, ADHD, and emotional problems.

³⁶⁴*CACNA1B* codes for the voltage-dependent N-type calcium channel subunit alpha-1B, a 365 constituent of the Cav2.2 channel. It too is a regulator of synaptic function that acts at the 366 presynaptic terminal to increase neurotransmitter release, which then influences postsynaptic 367 dendritic spine function 90 . In addition to having frequent infections and PANS, Case 3 was 368 diagnosed with Hodgkin's lymphoma, nodular sclerosis subtype. He was treated with ABVD, 369 and subsequently, autologous hematological stem cell transplant (HSCT). It is interesting to 370 note that Hodgkin's lymphoma is often found in patients with autoimmune problems and is 371 associated with abnormalities in IL-13 signaling, a cytokine produced by mast cells, eosinophils, 372 nuocytes, and Th2 cells $92-94$. This patient also has psoriasis, a Th17 associated autoimmune 373 disorder ^{95, 96}. This suggests the possibility that *CACNA1B* could have unrecognized effects on 374 the immune system by disrupting IL-13 and Th17 signaling leading to PANS, psoriasis, and 375 Hodgkin lymphoma. It is also interesting to note that his neuropsychiatric symptoms have 376 temporarily disappeared following HSCT. However, the follow-up period has only been a few 377 months, so it is too early to determine if the treatment has had a positive impact on his 378 neuropsychiatric symptoms. Autologous HSCT is an emerging technology for treating severe 379 autoimmune disorders ⁹¹. Given these observations, HSCT could prove to be an option for 380 treating a small subgroup of chronic, refractory, severely impaired PANS patients.

³⁸¹*GABRG2* codes for the gamma subunit of the GABA-A receptor, a ligand-gated chloride 382 channel. It is one of the most mutated genes in febrile seizures and other forms of epilepsy $97, 98$. ³⁸³We found a nonsense mutation, c.649C>T; p.Gln217X, in a child with severe PANS (case 5). 384 This is the same mutation previously found in sleep-related epilepsy ⁹⁹. Case 5 has a history of 385 febrile seizures.

³⁸⁶*SGCE* is a member of the sarcoglycan family of transmembrane proteins, a component 387 of the dystrophin-associated glycoprotein complex (DGC). Studies carried out in knockout mice

388 show that SGCE inhibits excitatory synapse formation, and that loss-of-function mutations lead 389 to an increase in excitatory synapses 100 . The DGC is involved in organizing aquaporin-4-390 containing protein complexes in glia that controls the formation of the glymphatic system. The 391 glymphatic system clears waste from the brain, and impaired glymphatic drainage has been found in neuroinflammation and dementia 101-103 ³⁹². Ultra-rare mutations in *SGCE* were found in 393 two unrelated subjects, cases 10 and 11.

394 Remarkably, *SGCE, CACNA1B,* and *GRIN2A* are well-known for causing Myoclonus-395 Dystonia (M-D), a hyperkinetic movement disorder, which is similar to tics, a diagnostic feature 396 of PANDAS. *SGCE,* in fact, is the most commonly mutated gene in M-D, with more than one-397 third of cases having truncating mutations in exon 3, which contains the del150Iso in-frame 398 mutation found in case 10¹⁰⁴⁻¹⁰⁶. Interestingly, patients with myoclonus caused by *SGCE* 399 mutations frequently have co-morbid psychiatric symptoms, including depression, anxiety, 400 bipolar disorder, phobias, alcoholism, and OCD 106 , symptoms that overlap with PANS. 401 Similarly, *GRIN2A* and *CACNA1B* mutations have been found in dystonic and other rare 402 movement disorders ^{85, 107-110}.

⁴⁰³These findings suggest that deleterious variants in these "neuronal" genes can result in ⁴⁰⁴a range of clinical phenotypes; M-D, ASD, developmental disabilities, epilepsy, and PANS, or 405 PANS co-morbid with these neurodevelopmental problems. It is important to add, however, that ⁴⁰⁶case 7 with the *PLCG2* ultra-rare variant c.617A>G, p.Y206F, as well as cases 12, 14, and 15, 407 who have mutations in *NLRC4* and *RAG1*, also had preexisting ASD prior to developing PANS. ⁴⁰⁸Thus, PANS/ASD co-morbidity is not restricted to cases with variants in genes typically ⁴⁰⁹associated with neurodevelopmental disorders. Other genetic factors causing the 410 neurodevelopmental problems, however, cannot be ruled out at this time. 411

⁴¹²**Connectivity Network**

⁴¹³To assess potential functional connections between the PANS candidate genes, we generated ⁴¹⁴a connectivity network to show the direct (solid lines) and indirect interactions (dotted lines) ⁴¹⁵(**Figure 3**). Included in the network are two additional PANS candidate genes, *MTHC2* and *BID,* 416 identified by one of us (R.T.) by GWAS that will be described in a separate paper. Central to the 417 network is the NF- κ B complex transcriptional regulator, which is activated by a variety of 418 immune, infectious, and non-immune (e.g., oxidative stress; toxins) stressors $111, 112$. Inappropriate activation of NF- κ B has been associated with inflammatory diseases 113 . Directly ⁴²⁰connected to the NF-κB hub are the PANS candidate genes; *PPM1D*, *PLCG2, NLRC4, RAG1,* ⁴²¹and *BID*, along with *CHK2* and *MTCH2*, which bind to PPM1D and BID, respectively. This hub 422 represents the set of PANS genes that likely to function through a disruption of peripheral and ⁴²³central innate immunity. The PANS candidate genes not directly connected to NF-κB expression 424 are those that are primarily expressed in the brain and cause neurodevelopmental disorders ⁴²⁵(*CACNA1B, SYNGAP1, GRIN2A, SGCE, GABRG2,* and *SHANK3*). 426 Interestingly, CaMKII, a biomarker from the Cunningham panel, is also centrally ⁴²⁷localized within the connectivity network and has a close relation to multiple candidate genes. 428 ⁴²⁹**Tissue and Cell Expression Pattern of PANS Candidate Genes** 430 To gain further insight into the mechanisms by which the PANS candidate genes lead to 431 neuroinflammation, we examined their expression pattern using several gene expression 432 resources, one of which is a single cell RNA-seq (scRNA-seq) database of white blood cells 433 (WBCs)¹⁶. This database contains gene expression patterns in control samples (N=6) and 434 hospitalized COVID-19 patients $(N=7)$. The candidate genes that have established effects on ⁴³⁵peripheral immune function, *PPM1D, CHK2,* and *RAG1,* are expressed in multiple cell types, ⁴³⁶*PLCG2* is primarily expressed in B-cells, and *NLRC4* in monocytes and neutrophils (**Figure S1**). 437 Interestingly, the expression of several genes was significantly affected in the COVID-19 438 patients. Most notably, a >100-fold increase in *NLRC4* expression was found in developing

439 neutrophils. This suggests that PANS-associated *NLRC4* mutations could lead to a marked 440 alteration in inflammasome function following infections. In addition, a >8-fold increase in *CHK2* 441 (also known as CHEK2) was found in interferon stimulated genes in T4 cells.

442 Although most of the "neuronal" PANS candidate genes are expressed at very low levels ⁴⁴³in WBCs, there are three notable exceptions. Most striking is *GABRG2,* which shows marginal ⁴⁴⁴expression in all WBCs except for T.gd cells (γδ T cells) in COVID-19 patients, where a >20-fold 445 increase in expression was found compared with controls. γδ T cells form a minor population of ⁴⁴⁶WBCs, but they increase dramatically during infections and play a key role in autoimmunity and 447 immune surveillance $114,115$. Perhaps more importantly from the perspective of PANS is the 448 finding that γδ T cells are found in meninges where they secrete the proinflammatory cytokine 449 IL-17a and participate in the development of anxiety-like behavior in mice 116 .

⁴⁵⁰*SYNGAP1* is expressed in many WBC subtypes, especially T cells. Strikingly, like ⁴⁵¹GABRG2, expression in γδ T cells increases nearly 4-fold in COVID-19 patients. And *SHANK3* 452 expression, while negligible in most WBCs, is abundant in a cluster consisting of two groups of 453 cells labeled as stem cells and eosinophils.

⁴⁵⁴These finding suggest that some neuronal PANS candidate genes that typically cause 455 neurodevelopmental disorders have unanticipated effects on immune function and their 456 expression is extremely responsive to an infectious disease stressor. Parenthetically, these 457 findings show that it will be important to monitor the potential impact of SARS-CoV-2 as an 458 infectious disease inducer of PANS.

⁴⁵⁹We next analyzed the cell and tissue expression pattern of each of the PANS candidate ⁴⁶⁰genes in normal human tissues using the GTEx dataset (**Figure S2**). The gene expression 461 patterns, based on bulk RNA-seq, generally conform to the functional groups described above 462 and the connectivity network. The genes affecting peripheral immunity that are connected to the ⁴⁶³NF-κB hub are expressed primarily in blood and EB-transformed lymphoblasts, and less so in

464 the brain, while the genes associated with neurodevelopmental disorders show the opposite 465 pattern. *PPM1D, RAG1*, and *SGCE* are highly expressed in both.

⁴⁶⁶To gain further insight into the expression of the PANS candidate genes in the nervous 467 system, we examined the cell type expression pattern in adolescent and fetal mouse brains. 468 One of the more striking observations in the adolescent brain is the relatively high level of *Chk2* ⁴⁶⁹expression in ependymal cells compared with all other brain cell types (**Figure 4; see Table S1** ⁴⁷⁰**for abbreviation key**). Ependymal cells line the ventricles and spinal canal and play an 471 important role in the production of CSF ¹¹⁷. As part of the choroid plexus, ependymal cells 472 regulate the blood-CSF barrier 118 . The choroid plexus plays a key role in neuroinflammatory 473 and neurodegenerative disorders and serves as a nexus for peripheral T-cells that can infiltrate 474 the brain, as well as access, when damaged, to proinflammatory cytokines, complement, and autoantibodies from the circulation to the brain parenchyma ¹¹⁹⁻¹²¹. *Ppm1d, Sgce, Plcg2,* ⁴⁷⁶*Syngap1,* and *Shank3* are also expressed in these cells, suggesting that their mutated versions

477 could disturb the blood-CSF barrier.

⁴⁷⁸Another interesting finding in adolescent nervous system is the relatively high level of 479 expression of *Ppm1d, Syngap1, Cacna1b,* and *Sgce* throughout the enteric nervous system. 480 The potential implications of this expression pattern will be described in the discussion section. ⁴⁸¹We also examined the single cell gene expression pattern of the PANS candidate genes 482 in the developing mouse brain, considering the fact that several cause neurodevelopmental ⁴⁸³disorders **(Figure S3)**. One of the more interesting findings is the expression of *Shank3,* which, 484 as expected, was diffusely expressed throughout the brain in both glutamatergic neurons and 485 GABAergic interneurons. However, the highest levels were seen in the choroid plexus and 486 cerebral vasculature. In fact, all of the PANS candidate genes, with the exception of *RAG1* are ⁴⁸⁷expressed in fetal choroid plexus, cerebral vasculature, and pericytes, with *Sgce, Chk2* and ⁴⁸⁸*Ppm1d,* along with *Shank3,* being most prominent. This is similar to the single cell expression

489 pattern seen in adolescent brains (**Figure 4**), reinforcing the idea that disruption of the blood-490 CSF barrier and/or the BBB is playing a role in the emergence of PANS.

⁴⁹²**Discussion**

493 Genetic contributions to disease can be divided into common variants that have relatively small ⁴⁹⁴biological effects, which are generally identified by large-scale GWAS, and high impact, 495 biologically significant ultra-rare variants. So far, no reports have been published in which 496 common variants were identified, although there is a small, unpublished study derived from a 497 direct-to-consumer DNA testing service in which five SNPs associated with PANS and PANDAS 498 were found (see Web Resources), two of which occur in credible candidate genes (rs5029936 in ⁴⁹⁹*TNFAIP3*; rs76298532 in *MCPH1*).

500 **In the current study, we searched for ultra-rare variants in PANS patients using next** 501 generation sequencing. For the European cohort, cases were selected for their severity. The 502 index case was a teenage girl with severe, chronic PANS who was found, along with her 503 affected brother, to have an ultra-rare *PPM1D* mutation (c.131C>G; p.S44W) (**Figure 1**). This ⁵⁰⁴mutation is upstream of the phosphatase domain and its effect on PPM1D catalytic function is 505 not immediately clear. However, the nearby serine amino acids S40 and S46 could be playing a 506 role the development of PANS in this family. These are substrates for the serine kinases 507 DYRK1A and HIPK2, which cause IDD, ASD, and abnormal feeding behavior when mutated 122 -508 ¹²⁴. DYRK1A also has important effects on innate immunity by regulating the balance between 509 Th17 and T regulatory (Treg) cells, T cell subsets involved in the development of autoimmune 510 diseases and inflammation ¹²⁵⁻¹²⁹. Interestingly, Th17 mediates the effects of *Streptococcus* on 511 neuroinflammation in a mouse model of PANDAS by causing a breach in the BBB, with 512 subsequent brain infiltration of Th17 lymphocytes $125, 130-132$. HIPK2 regulates PPM1D protein 513 levels by inducing its degradation in DNA-damaged cells, triggering activation of the DNA repair 514 pathway ¹³³. HIPK2 expression increases in LPS-stimulated macrophages, and its knockdown

515 attenuates the expression of inflammatory cytokines $^{134, 135}$. S46 is also a HIPK2 substrate. 516 Thus, an effect of S44W on immune regulation could be secondary to altered interactions 517 between DYRK1A and HIPK2 with PPM1D.

518 Following the discovery of this variant, we identified an additional eight other severely 519 affected patients through a PANS/PANDAS advocacy group that primarily operates in the 520 European Union. WGS was carried out, which resulted in the identification of ultra-rare variants 521 in plausible candidate genes in every patient in the European cohort. Although there is a clear 522 ascertainment bias for these participants, the findings of ultra-rare variants in the same genes 523 and other plausible candidates in an unselected, modestly sized population in the United States 524 cohort suggest that severe PANS is often caused by biologically powerful ultra-rare genetic 525 variants. The condition can be viewed as a heterogenous genetically dominant disorder, albeit, 526 with reduced penetrance. Evidence that penetrance is not 100% is seen in several families in 527 whom transmission occurred from a carrier parent who do not have neuropsychiatric problems 528 typical of PANS. The *PPM1D* variant, for example, was inherited from an asymptomatic father ⁵²⁹who has a family history of autoimmune disorders, In addition, two siblings of case 10 (*SGCE* 530 (del150 Iso; c.450_452) also inherited the variant. One has asthma, allergies, and contact 531 dermatitis, but no neuropsychiatric problems; The other has similar atopic problems. Although 532 he does not have PANS, he has developed debilitating, recurrent cluster-type headaches. ⁵³³Whether the headaches are a manifestation of neuroinflammation, or vasculitis is not known. 534 Finally, case 9 (NLRC4 c.772T>C; p.C258R), inherited the mutation from a mother who 535 has with a history of psoriasis and arthritis. She was diagnosed with focal epilepsy as an adult 536 but has no history of PANS. A younger sibling with the same variant has a history suggestive of 537 PANS but has not yet been clinically ascertained.

538 The lack of complete penetrance is consistent with a small monozygotic twin study in 539 PANDAS that showed a range of different phenotypes, including complete discordance ¹³⁶.

540 Similarly, the MZ twin concordance rate in autoimmune disorders ranges from approximately 541 20% -70% depending on the condition 137 .

542 This suggests that environmental factors are playing a role in PANS. In the case of the 543 generation divide between carrier parents and their affected children, changes in the prevalence 544 of certain strains of bacteria and antigenic shifts in viruses implicated as PANS triggers, could 545 account for their different clinical outcomes. *Borrelia burgdorferi*, which causes Lyme disease, is 546 an example of an infectious disease that has markedly increased in prevalence in the past 30 547 years, while antigenic shifts in viruses that cause influenza or common cold are examples of 548 infectious diseases that are subject to rapid genetic changes. In addition, the current generation 549 of youth might be exposed to non-infectious environmental triggers that were not as prevalent in 550 past generations. Although unaffected carrier parents might be exposed to the same infectious 551 agents or non-infectious stressors that are currently triggering PANS flareups in their children, 552 age-related differences in the blood-CSF barrier or BBB could make the adult brain less 553 susceptible ¹³⁸. Genetic background and stochastic T cell receptor and IgG gene rearrangement 554 could also explain reduced penetrance in families, and discordance in MZ twins.

555 The candidate genes identified in this study can be broadly separated into those that 556 have established effects on peripheral innate and adaptive immunity, and those that affect 557 synaptic function in particular the PSD-95 complex. However, this peripheral vs central 558 dichotomy, which could potentially explain the presence or absence of immune markers and 559 response to immunomodulators, is an oversimplification. First, as noted earlier, several PANS 560 candidate genes that have effects on peripheral innate immunity, such as *PPM1D, PLCG2*, and ⁵⁶¹*NLRC4,* also affect microglia function and are differentially expressed in those cells following an 562 immune challenge. Second, patients with mutations in genes that function as synaptic 563 regulators, such as *SHANK3*, can respond to IVIG, as shown by Bey et al ⁸⁰. Similarly, our 564 cases with ultra-rare variants in *SHANK3*, *CACNA1B*, *SGCE* and *GABRG2* also responded to ⁵⁶⁵IVIG. Third, as shown in **Figure S1**, neuronal genes like *SHANK3, GABRG2* and *SYNGAP1*

566 show expression patterns that strongly support an adverse effect on immune function, in 567 particular γδ T-cells, based on their markedly altered expression during upon an infectious 568 disease challenge. Fourth, some of the neuronal PANS candidate genes that have effects on 569 synaptic function, such as *SHANK3, SGCE, CHK2, and PPM1D*, are also expressed in the 570 choroid plexus and brain vascular endothelium, which could potentially connect peripheral 571 inflammation with neuroinflammation through disruption of the brain/CSF barrier and BBB 572 caused by mutations in these genes. SHANK3 is a cytoskeletal protein that regulates 573 dlutamatergic synaptogenesis, but it can also function as a scaffolding protein in epithelial 574 cells¹³⁹. In addition, PPM1D has been found to regulate BBB function and neuroinflammation in 575 a co-culture of human brain-microvascular endothelial cells and human astrocytes treated with 576 LPS¹⁴⁰.

577 Expression of PANS candidate genes in the choroid plexus and vascular endothelium 578 during fetal development is also interesting when considering the phenomenon known as 579 maternal immune activation (MIA), a proinflammatory state in pregnancy triggered by infection, 580 maternal autoimmune disorders, and non-infectious peripheral inflammation^{141, 142}. The fetal 581 brain is vulnerable to changes in the maternal/fetal environment, such as MIA $141-143$, which has 582 been shown in animal models to adversely affect brain development, leading to behaviors and 183 learning difficulties similar to those seen in patients with ASD and schizophrenia ¹⁴⁴⁻¹⁵². ⁵⁸⁴Consequently, it is conceivable that the pathophysiological process that leads to the 585 development of PANS and co-morbid neurodevelopmental disorders could begin during fetal life 586 in some patients and genetic subgroups.

587 An effect on the choroid plexus and vasculature endothelium (and γδ T cells) could also 588 explain the response to IVIG in those patients harboring mutations in the "neuronal" subgroup of 589 candidate genes. IVIG can reduce neuroinflammation by affecting T-cell/microglia crosstalk, 590 reducing levels of proinflammatory cytokines, blocking Fcγ receptors, inhibiting complement, 591 and repairing disrupted brain-CSF barriers ¹⁵³⁻¹⁵⁶.

⁵⁹²While extra-neuronal effects of synaptic proteins could have an impact on the 593 development of PANS, their effects on synaptogenesis in the development of PANS should also 594 be considered. One possible mechanism is a defect in PSD-95 assembly and glutamate 595 receptor function leading to abnormal synaptic remodeling. This could trigger over-activation of 596 microglia, which in turn would release proinflammatory cytokines, complement, prostaglandins, 597 proteinases, and reactive oxygen species, causing neuroinflammation. An extension of this 598 model is that a similar overactivation of microglia could be driven by a primary, intrinsic defect 599 caused by PANS candidate genes that are highly expressed in microglia, but not neurons (e.g., ⁶⁰⁰*PLCG2, NLRC4*). This is consistent with our finding that *Plcg2, Sgce,* and *Nlrc4* are differentially ⁶⁰¹expressed in LPS-treated microglia (**Figure 2)**. Non-neuronal stimuli that might induce microglia 602 overactivation in PANS is open to speculation, but could include oxidative stress, environmental 603 toxins, and peripheral infection/inflammation.

⁶⁰⁴Finally, it is interesting to consider the implications of the finding that several PANS 605 candidate genes are also mutated in D-M, ASD, and other neurodevelopmental disorders. ⁶⁰⁶PANS is occurring as an independent phenotype in some of our cases, and as a comorbid trait 607 in others. These comorbid cases are like the *SHANK3-mutated patients reported by Bey et al.* 608 ⁸⁰. Similarly, Jones et al., described eight children with ASD and other neurodevelopmental 609 disorders, with a strong family history of maternal autoimmune thyroid disorders, who presented 610 with infection-induced, abrupt onset of neuropsychiatric symptoms, primarily OCD and tics, 611 along with autistic or global regression¹⁵⁷. Overall, comorbid ASD and other neuropsychiatric 612 disorders were found in nine cases in our study, not including cases 1 and 2 who were typically 613 developing prior to the onset of PANS and the development of chronic symptoms (Table 2)

⁶¹⁴The development of either PANS, a neurodevelopmental disorder, or PANS comorbid ⁶¹⁵with a neurodevelopmental disorder, could be due to subtle mutation-specific effects on 616 neuronal or immune function, environmental factors (e.g., MIA), or genetic background. A

617 genetic connection between PANS, D-M, ASD, and other neurodevelopmental disorders also 618 supports the idea that an inflammatory component is involved in the pathogenesis of subgroups 619 of patients with schizophrenia and ASD, as suggested by numerous genetic and molecular 620 studies $157-164$. At the very least, an inflammatory component leading to the abrupt onset of 621 PANS superimposed on a chronic neurodevelopmental disorder is a real phenomenon that 622 needs to be recognized by the medical community because immunological therapies like IVIG 623 could be very helpful.

624

⁶²⁵**Expression of PANS/PANDAS candidate genes in the enteric nervous system**

626 Another aspect of our genetic analysis was the finding that many of the candidate genes we 627 identified are expressed in enteric neurons, which could perhaps explain the abdominal 628 complaints experienced by PANS patients 3 . In addition, enteric expression could be playing a 629 direct role in the development of PANS in some genetic subgroups. For example, cholinergic 630 fibers come in close contact with macrophages, plasma cells, and lymphocytes located in the 631 intestinal mucosa, and gut-associated lymphoid tissue 165 . In addition, patients with 632 PANS/PANDAS have been found to have differences in the gut microbiome compared with 633 controls $^{166, 167}$, and an increase in gut-derived LPS and markers of oxidative stress 168 . More 634 specific to the candidate genes we identified, several have established effects on the gut. 635 PPM1D, for example, has been found to have a protective effect on oxidation stress-induced gut 636 permeability ¹⁶⁵. In addition, *Shank3* knockout mice have an altered microbiota composition, an 637 increase in LPS levels in the liver, and altered gut permeability $169, 170$. Furthermore, variants in 638 and altered gut permeability *NLRC4* have been implicated in inflammatory bowel disease ^{171, 172} 639 **Overall, the expression of PANS candidate genes in the enteric nervous system fits into** 640 the emerging idea that disruption of the gut-brain connection and the gut microbiome are

641 involved in the pathogenesis of ASD, neurodegeneration, neuropsychiatric disorders,

642 autoimmune disorders, and PANS $173-177$.

⁶⁴³In summary, we identified ultra-rare genetic variants in PANS patients that appear to ⁶⁴⁴function at multiple levels of the neuroinflammatory circuit, including peripheral and central ⁶⁴⁵innate immunity, synaptogenesis, the blood-CSF barrier, and perhaps the enteric nervous 646 system. Dissecting the molecular and cellular pathogenesis of the PANS candidate variants will 647 require an analysis in mouse models, as well as patient-specific induced pluripotent stem cells, 648 from which cells of importance in the development of PANS, such as neurons, microglia, 649 astrocytes, neuronal epithelium, vascular endothelium, and gut organoids can be derived. ⁶⁵¹**Supplemental Information** ⁶⁵²**Supplemental data include 3 figures and 1 table, Supplemental Note: Case Reports** 653 ⁶⁵⁴**Acknowledgments** ⁶⁵⁵The authors want to thank EXPAND for directing researchers to PANS cases throughout the ⁶⁵⁶European Union, and Erika Pedrosa for copy editing the manuscript. HML is supported by the 657 National Institute of Child Health and Human Development NIH/NICHD; P30 HD071593 to the ⁶⁵⁸Albert Einstein College of Medicine's Rose F. Kennedy Intellectual and Developmental 659 Disabilities Research Center. The Lachman lab also receives support from the Janice C. ⁶⁶⁰Blanchard Family Fund. P.J. van der Spek is supported by EU H2020 grants, an ImmunAID 661 grant (ID: 7792950), and a MOODSTRATIFICATION grant (ID: 754740). The Bioinformatics 662 infrastructure and team is supported by grants from KWF, NWO/ZonMW and the Dutch Heart 663 foundation through the BDVA initiated H2020 Bigmedilytics program on Personalized Medicine. 664 Neither the authors nor their academic institutions received payment or services from a third 665 party for any aspect of the submitted work including the study design and manuscript 666 preparation.

- 667 **The authors dedicate this paper to Dr. Paul Janssen whose ideas about the role of the**
- 668 immune system in tics and psychosis help form the framework for this research project, and to
- 669 participating families for their courage and support.
-

⁶⁷¹**Declaration of Interests**

- 672 The authors declare no competing interests
-

⁶⁷⁴**Web Resources**

- 675 https://www.nimh.nih.gov/health/publications/pandas/index.shtml
- 676 https://www.expand.care
- 677 http://rstats.immgen.org/Skyline_COVID-19/skyline.html
- 678 https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis
- 679 https://www.omim.org
- 680 https://www.pandaspansinstitute.com
- 681 https://gene.sfari.org/database/human-gene
- 682 https://www.gtexportal.org/home
- 683 https://genome.ucsc.edu
- 684 http://mousebrain.org
- 685 https://www.phosphosite.org//homeAction.action
- ⁶⁸⁶https://osf.io/q4y2k/
-

⁶⁸⁸**References**

- ⁶⁸⁹1. Swedo, S.E., Leonard, H.L., Mittleman, B.B., Allen, A.J., Rapoport, J.L., Dow, S.P., Kanter,
- ⁶⁹⁰M.E., Chapman, F., Zabriskie, J. (1997). Identification of children with pediatric autoimmune
- 691 neuropsychiatric disorders associated with streptococcal infections by a marker associated with
- 692 rheumatic fever. Am. J. Psychiatry 154, 110-112.

- 693 2. Calaprice, D., Tona, J., Parker-Athill, E.C., Murphy, T.K. (2017). A Survey of Pediatric Acute-
- 694 Onset Neuropsychiatric Syndrome Characteristics and Course. J. Child Adolesc.
- 695 Psychopharmacol. 27, 607-618.
- ⁶⁹⁶3. Chang, K., Frankovich, J., Cooperstock, M., Cunningham, M.W., Latimer, M.E., Murphy, T.K.,
- 697 Pasternack, M., Thienemann, M., Williams, K., Walter, J. et al. (2015). Clinical evaluation of
- 698 youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the
- ⁶⁹⁹2013 PANS Consensus Conference. J. Child Adolesc. Psychopharmacol. 25, 3-13.
- ⁷⁰⁰4 Wilbur, C., Bitnun, A., Kronenberg, S., Laxer, R.M., Levy, D.M., Logan, W.J., Shouldice, M.,
- 701 Yeh, E.A. (2019). PANDAS/PANS in childhood: Controversies and evidence. Paediatr. Child.
- 702 Health. 24, 85-91.
- ⁷⁰³5. Chiarello, F., Spitoni, S., Hollander, E., Matucci Cerinic, M., Pallanti, S. (2017). An expert
- 704 opinion on PANDAS/PANS: highlights and controversies. Int. J. Psychiatry Clin. Pract. 21, 91-705 98.
- ⁷⁰⁶6. Gilbert, D.L. (2019). Inflammation in Tic Disorders and Obsessive-Compulsive Disorder: Are 707 PANS and PANDAS a Path Forward? J. Child Neurol. 34, 598-611.
- 708 7. Zheng, J., Frankovich, J., McKenna, E.S., Rowe, N.C., MacEachern, S.J., Ng, N.N., Tam,
- ⁷⁰⁹L.T., Moon, P.K., Gao, J., Thienemann, M. et al. (2020). Association of Pediatric Acute-Onset
- 710 Neuropsychiatric Syndrome With Microstructural Differences in Brain Regions Detected via
- 711 Diffusion-Weighted Magnetic Resonance Imaging. JAMA Netw. Open 3, e204063.
- 712 8. Vitaliti, G., Tabatabaie, O., Matin, N., Ledda, C., Pavone, P., Lubrano, R., Serra, A., Di
- 713 Mauro, P., Cocuzza, S., Falsaperla, R. (2015). The usefulness of immunotherapy in pediatric
- 714 neurodegenerative disorders: A systematic review of literature data. Hum. Vaccin Immunother.
- 715 11, 2749-2763.

- ⁷¹⁶9. Melamed, I., Kobayashi, R.H., O'Connor, M., Kobayashi, A.L., Schechterman, A., Heffron, M.,
- 717 Canterberry, S., Miranda, H., Rashid, N. (2021). Evaluation of Intravenous Immunoglobulin in
- 718 Pediatric Acute-Onset Neuropsychiatric Syndrome. J. Child Adolesc. Psychopharmacol. 31,
- 719 118-128.
- ⁷²⁰10. Frankovich, J., Leibold, C.M., Farmer, C., Sainani, K., Kamalani, G., Farhadian, B., Willett,
- 721 T., Park, J.M., Sidell, D., Ahmed, S. et al. (2018). The Burden of Caring for a Child or
- 722 Adolescent With Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): An Observational
- ⁷²³Longitudinal Study. J. Clin. Psychiatry 80, 17m12091. doi: 10.4088/JCP.17m12091.
- 724 11. Gromark, C., Hesselmark, E., Djupedal, I.G., Silverberg, M., Horne, A., Harris, R.A.,
- 725 Serlachius, E., Mataix-Cols, D. (2021). A Two-to-Five Year Follow-Up of a Pediatric Acute-
- 726 Onset Neuropsychiatric Syndrome Cohort. Child Psychiatry Hum. Dev., 1-11.
- 727 12. Frankovich, J., Thienemann, M., Rana, S., Chang, K. (2015). Five youth with pediatric
- 728 acute-onset neuropsychiatric syndrome of differing etiologies. J. Child Adolesc.
- 729 Psychopharmacol. 25, 31-37.
- ⁷³⁰13. Erikson, G.A., Bodian, D.L., Rueda, M., et al. (2016) Whole-genome sequencing of a
- 731 healthy aging cohort. Cell. 2016;165: 1002-1011.
- ⁷³²14. Drmanac, R., Sparks, A.B., Callow, M.J., Halpern, A.L., Burns, N.L., Kermani, B.G.,
- 733 Carnevali, P., Nazarenko, I., Nilsen, G.B., Yeung, G. et al. (2010). Human genome sequencing
- 734 using unchained base reads on self-assembling DNA nanoarrays. Science 327, 78-81.
- ⁷³⁵15. Greenhalgh, A.D., Zarruk, J.G., Healy, L.M., Baskar Jesudasan, S.J., Jhelum, P., Salmon,
- 736 C.K., Formanek, A., Russo, M.V., Antel, J.P., McGavern, D.B. et al. (2018). Peripherally derived
- 737 macrophages modulate microglial function to reduce inflammation after CNS injury. PLoS Biol.
- 738 16, e2005264.

- ⁷³⁹16. Wilk, A.J., Rustagi, A., Zhao, N.Q., Roque, J., Martinez-Colon, G.J., McKechnie, J.L., Ivison,
- ⁷⁴⁰G.T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020). A single-cell atlas of the peripheral
- 741 immune response to severe COVID-1. Nat Med. Jul; 26(7), 1070–1076.
- 742 17. GTEx Consortium. (2020). The GTEx Consortium atlas of genetic regulatory effects across
- ⁷⁴³human tissues. Science Sep 11;369(6509):1318-1330.
- ⁷⁴⁴18. Zeisel, A., Hochgerner, H., Lönnerberg, P., Johnsson, A., Memic, F., van der Zwan, J.,
- 745 Häring, M., Braun, E., Borm, L.E., La Manno, G. et al. (2018). Molecular Architecture of the
- 746 Mouse Nervous System. Cell 174, 999-1014.e22.
- ⁷⁴⁷19. La Manno, G., Siletti, K., Furlan, A., Gyllborg, D., Vinsland, E., Langseth, C.M., Khven, I.,
- 748 Johnsson, A., Nilsson, M., Lönnerberg, P. et al. Molecular architecture of the developing mouse 749 brain. bioRxiv (2020)
- ⁷⁵⁰20. Gagliano, A., Galati, C., Ingrassia, M., Ciuffo, M., Alquino, M.A., Tanca, M.G., Carucci, S.,
- 751 Zuddas, A., Grossi, E. (2020). Pediatric Acute-Onset Neuropsychiatric Syndrome: A Data
- 752 Mining Approach to a Very Specific Constellation of Clinical Variables. J Child Adolesc
- 753 Psychopharmacol. Oct;30(8):495-511.
- ⁷⁵⁴21. Fernell, E., Sundin, M., Fasth, A., Dinkler, L., Galazka, M., Gillberg, C., Johnson, M. (2021).
- 755 Paediatric Acute onset Neuropsychiatric Syndrome: Exploratory study finds no evidence of HLA
- 756 class II association but high rate of autoimmunity in first-degree relatives. Acta Paediatr.
- 757 22. Burgess, D.J. (2021). The TOPMed genomic resource for human health. Nat. Rev. Genet. ⁷⁵⁸Apr;22(4):200. doi: 10.1038/s41576-021-00343-x.
- ⁷⁵⁹23. Yoda, A., Xu, X.Z., Onishi, N., Toyoshima, K., Fujimoto, H., Kato, N., Oishi, I., Kondo, T.,
- 760 Minami, Y. (2006). Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-

- 761 terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1. J. Biol.
- 762 Chem. 281, 24847-24862.
- ⁷⁶³24. Cardoso, M., Paulo, P., Maia, S., Teixeira, M.R. (2016). Truncating and missense PPM1D
- 764 mutations in early-onset and/or familial/hereditary prostate cancer patients. Genes
- 765 Chromosomes Cancer 55, 954-961.
- ⁷⁶⁶25. Swisher, E.M., Harrell, M.I., Norquist, B.M., Walsh, T., Brady, M., Lee, M., Hershberg, R.,
- 767 Kalli, K.R., Lankes, H., Konnick, E.Q. et al. (2016). Somatic Mosaic Mutations in PPM1D and
- 768 TP53 in the Blood of Women With Ovarian Carcinoma. JAMA Oncol. 2, 370-372.
- 769 26. Alzahrani, A.S., Murugan, A.K., Qasem, E., Alswailem, M.M., AlGhamdi, B., Moria, Y., Al-
- 770 Hindi, H. (2018). Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid
- 771 Cancer Genome Atlas (TCGA) in a large series of thyroid cancer. Endocrine.
- ⁷⁷²27. Jansen, S., Geuer, S., Pfundt, R., Brough, R., Ghongane, P., Herkert, J.C., Marco, E.J.,
- 773 Willemsen, M.H., Kleefstra, T., Hannibal, M. et al. (2017). De Novo Truncating Mutations in the
- 774 Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome. Am. J. Hum.
- 775 Genet. 100, 650-658.
- ⁷⁷⁶28. Lelieveld, S.H., Reijnders, M.R., Pfundt, R., Yntema, H.G., Kamsteeg, E.J., de Vries, P., de
- 777 Vries, B.B., Willemsen, M.H., Kleefstra, T., Lohner, K. et al. (2016). Meta-analysis of 2,104 trios
- 778 provides support for 10 new genes for intellectual disability. Nat. Neurosci. 19, 1194-1196.
- ⁷⁷⁹29. Porrmann, J., Rump, A., Hackmann, K., Di Donato, N., Kahlert, A.K., Wagner, J., Jahn, A.,
- ⁷⁸⁰Eger, I., Flury, M., Schrock, E. et al. (2018). Novel truncating PPM1D mutation in a patient with
- 781 intellectual disability. Eur. J. Med. Genet.
- 782 30. Deciphering Developmental Disorders Study. (2017). Prevalence and architecture of de
- 783 novo mutations in developmental disorders. Nature 542, 433-438.

- ⁷⁸⁴31. Porrmann, J., Rump, A., Hackmann, K., Di Donato, N., Kahlert, A.K., Wagner, J., Jahn, A.,
- ⁷⁸⁵Eger, I., Flury, M., Schrock, E. et al. (2019). Novel truncating PPM1D mutation in a patient with
- 786 intellectual disability. Eur. J. Med. Genet. 62, 70-72.
- ⁷⁸⁷32. Sun, B., Hu, X., Liu, G., Ma, B., Xu, Y., Yang, T., Shi, J., Yang, F., Li, H., Zhang, L. et al.
- ⁷⁸⁸(2014). Phosphatase Wip1 negatively regulates neutrophil migration and inflammation. J.
- 789 Immunol. 192, 1184-1195.
- ⁷⁹⁰33. Yi, W., Hu, X., Chen, Z., Liu, L., Tian, Y., Chen, H., Cong, Y.S., Yang, F., Zhang, L.,
- 791 Rudolph, K.L. et al. (2015). Phosphatase Wip1 controls antigen-independent B-cell
- 792 development in a p53-dependent manner. Blood 126, 620-628.
- ⁷⁹³34. Liu, G., Hu, X., Sun, B., Yang, T., Shi, J., Zhang, L., Zhao, Y. (2013). Phosphatase Wip1
- 794 negatively regulates neutrophil development through p38 MAPK-STAT1. Blood 121, 519-529.
- 795 35. Tang, Y., Pan, B., Zhou, X., Xiong, K., Gao, Q., Huang, L., Xia, Y., Shen, M., Yang, S., Liu,
- 796 H. et al. (2017). Wip1-dependent modulation of macrophage migration and phagocytosis. Redox 797 Biol. 13, 665-673.
- 798 36. Brichkina, A., Bulavin, D.V. (2012). WIP-ing out atherosclerosis with autophagy. Autophagy ⁷⁹⁹8, 1545-1547.
- ⁸⁰⁰37. Zhang, Q., Zhang, C., Chang, F., Liang, K., Yin, X., Li, X., Zhao, K., Niu, Q., Tian, Z. (2016).
- 801 Wip 1 inhibits intestinal inflammation in inflammatory bowel disease. Cell. Immunol. 310, 63-70.
- 802 38. Dudgeon, C., Shreeram, S., Tanoue, K., Mazur, S.J., Sayadi, A., Robinson, R.C., Appella,
- ⁸⁰³E., Bulavin, D.V. (2013). Genetic variants and mutations of PPM1D control the response to DNA
- 804 damage. Cell. Cycle 12, 2656-2664.

- 805 39. Kleiblova, P., Stolarova, L., Krizova, K., Lhota, F., Hojny, J., Zemankova, P., Havranek, O.,
- 806 Vocka, M., Cerna, M., Lhotova, K. et al. (2019). Identification of deleterious germline CHEK2
- 807 mutations and their association with breast and ovarian cancer. Int. J. Cancer 145, 1782-1797.
- ⁸⁰⁸40. Stolarova, L., Kleiblova, P., Janatova, M., Soukupova, J., Zemankova, P., Macurek, L.,
- 809 Kleibl, Z. (2020). CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than
- 810 Checkmate. Cells 9, 2675. doi: 10.3390/cells9122675.
- ⁸¹¹41. Helgeland, H., Gabrielsen, I., Akselsen, H., Sundaram, A.Y.M., Flåm, S.T., Lie, B.A. (2020).
- 812 Transcriptome profiling of human thymic CD4+ and CD8+ T cells compared to primary
- 813 peripheral T cells. BMC Genomics 21, 350-020-6755-1.
- 814 42. Davari, K., Frankenberger, S., Schmidt, A., Tomi, N.S., Jungnickel, B. (2014). Checkpoint
- 815 kinase 2 is required for efficient immunoglobulin diversification. Cell. Cycle 13, 3659-3669.
- 816 43. Maffucci, P., Chavez, J., Jurkiw, T.J., O'Brien, P.J., Abbott, J.K., Reynolds, P.R., Worth, A.,
- 817 Notarangelo, L.D., Felgentreff, K., Cortes, P. et al. (2018). Biallelic mutations in DNA ligase 1
- 818 underlie a spectrum of immune deficiencies. J. Clin. Invest. 128, 5489-5504.
- ⁸¹⁹44. Chen, M.Y., Hsu, W.C., Hsu, S.C., Yang, Y.S., Chuang, T.H., Lin, W.J., Tan, T.H., Su, Y.W.
- 820 (2019). PP4 deficiency leads to DNA replication stress that impairs immunoglobulin class switch
- 821 efficiency. Cell Death Differ. 26, 1221-1234.
- ⁸²²45. Dujka, M.E., Puebla-Osorio, N., Tavana, O., Sang, M., Zhu, C. (2010). ATM and p53 are
- 823 essential in the cell-cycle containment of DNA breaks during $V(D)$ J recombination in vivo.
- 824 Oncogene 29, 957-965.
- ⁸²⁵46. Martín-Nalda, A., Fortuny, C., Rey, L., Bunney, T.D., Alsina, L., Esteve-Solé, A., Bull, D.,
- 826 Anton, M.C., Basagaña, M., Casals, F. et al. (2020). Severe Autoinflammatory Manifestations

- 827 and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations. J. Clin. Immunol. 40, 828 987-1000.
- ⁸²⁹47. Zhou, Q., Lee, G.S., Brady, J., Datta, S., Katan, M., Sheikh, A., Martins, M.S., Bunney, T.D.,
- 830 Santich, B.H., Moir, S. et al. (2012). A hypermorphic missense mutation in PLCG2, encoding
- 831 phospholipase Cy2, causes a dominantly inherited autoinflammatory disease with
- 832 immunodeficiency. Am. J. Hum. Genet. 91, 713-720.
- ⁸³³48. Ombrello, M.J., Remmers, E.F., Sun, G., Freeman, A.F., Datta, S., Torabi-Parizi, P.,
- 834 Subramanian, N., Bunney, T.D., Baxendale, R.W., Martins, M.S. et al. (2012). Cold urticaria,
- 835 immunodeficiency, and autoimmunity related to PLCG2 deletions. N. Engl. J. Med. 366, 330-836 338.
- 837 49. Yu, P., Constien, R., Dear, N., Katan, M., Hanke, P., Bunney, T.D., Kunder, S., Quintanilla-
- 838 Martinez, L., Huffstadt, U., Schröder, A. et al. (2005). Autoimmunity and inflammation due to a

839 gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+

840 entry. Immunity 22, 451-465.

- 841 50. Novice, T., Kariminia, A., Del Bel, K.L., Lu, H., Sharma, M., Lim, C.J., Read, J., Lugt, M.V.,
- 842 Hannibal, M.C., O'Dwyer, D. et al. (2020). A Germline Mutation in the C2 Domain of PLCγ2
- 843 Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases. J. Clin. 844 Immunol. 40, 267-276.
- 845 51. Alehashemi, S., Goldbach-Mansky, R. (2020). Human Autoinflammatory Diseases Mediated
- 846 by NLRP3-, Pyrin-, NLRP1-, and NLRC4-Inflammasome Dysregulation Updates on Diagnosis,
- 847 Treatment, and the Respective Roles of IL-1 and IL-18. Front. Immunol. 11, 1840.
- 848 52. Kay, C., Wang, R., Kirkby, M., Man, S.M. (2020). Molecular mechanisms activating the
- 849 NAIP-NLRC4 inflammasome: Implications in infectious disease, autoinflammation, and cancer.
- 850 Immunol. Rev. 297, 67-82.

- 851 53. Andrade, W.A., Zamboni, D.S. (2020). NLRC4 biology in immunity and inflammation. J.
- 852 Leukoc. Biol. 108, 1117-1127.
- ⁸⁵³54. Iqubal, A., Ahmed, M., Ahmad, S., Sahoo, C.R., Iqubal, M.K., Haque, S.E. (2020).
- 854 Environmental neurotoxic pollutants: review. Environ. Sci. Pollut. Res. Int. 27, 41175-41198.
- ⁸⁵⁵55. Liang, J., Alfano, D.N., Squires, J.E., Riley, M.M., Parks, W.T., Kofler, J., El-Gharbawy, A.,
- 856 Madan-Kheterpal, S., Acquaro, R., Picarsic, J. (2017). Novel NLRC4 Mutation Causes a
- 857 Syndrome of Perinatal Autoinflammation With Hemophagocytic Lymphohistiocytosis,
- 858 Hepatosplenomegaly, Fetal Thrombotic Vasculopathy, and Congenital Anemia and Ascites.
- 859 Pediatr. Dev. Pathol. 20, 498-505.
- 860 56. Romberg, N., Vogel, T.P., Canna, S.W. (2017). NLRC4 inflammasomopathies. Curr. Opin.
- 861 Allergy Clin. Immunol. 17, 398-404.
- ⁸⁶²57. Sundaram, B., Kanneganti, T.D. (2021). Advances in Understanding Activation and Function 863 of the NLRC4 Inflammasome. Int. J. Mol. Sci. 22, 1048. doi: 10.3390/ijms22031048.
- 864 58. Ip, W.K., Medzhitov, R. (2015). Macrophages monitor tissue osmolarity and induce
- 865 inflammatory response through NLRP3 and NLRC4 inflammasome activation. Nat. Commun. 6, 866 6931.
- 867 59. Sandall, C.F., Ziehr, B.K., MacDonald, J.A. (2020). ATP-Binding and Hydrolysis in
- 868 Inflammasome Activation. Molecules 25, 4572. doi: 10.3390/molecules25194572.
- ⁸⁶⁹60. Hu, Z., Yan, C., Liu, P., Huang, Z., Ma, R., Zhang, C., Wang, R., Zhang, Y., Martinon, F.,
- 870 Miao, D. et al. (2013). Crystal structure of NLRC4 reveals its autoinhibition mechanism. Science ⁸⁷¹341, 172-175.

- 872 61. Moghaddas, F., Zeng, P., Zhang, Y., Schützle, H., Brenner, S., Hofmann, S.R., Berner, R.,
- 873 Zhao, Y., Lu, B., Chen, X. et al. (2018). Autoinflammatory mutation in NLRC4 reveals a leucine-
- 874 rich repeat (LRR)-LRR oligomerization interface. J. Allergy Clin. Immunol. 142, 1956-1967.e6.
- ⁸⁷⁵62. Delmonte, O.M., Villa, A., Notarangelo, L.D. (2020). Immune dysregulation in patients with
- 876 RAG deficiency and other forms of combined immune deficiency. Blood 135, 610-619.
- ⁸⁷⁷63. Erman, B., Çipe, F. (2020). Genetic Screening of the Patients with Primary
- 878 Immunodeficiency by Whole-Exome Sequencing. Pediatr Allergy Immunol Pulmonol
- 879 Mar; 33(1): 19-24.
- ⁸⁸⁰64. Abraham, R.S., Recher, M., Giliani, S., Walter, J.E., Lee, Y.N., Frugoni, F., Maddox, D.E.,
- 881 Kirmani, S., Notarangelo, L.D. (2013). Adult-onset manifestation of idiopathic T-cell
- 882 Iymphopenia due to a heterozygous RAG1 mutation. J. Allergy Clin. Immunol. 131, 1421-1423.
- ⁸⁸³65. Li, D., Zhang, L., Huang, X., Liu, L., He, Y., Xu, L., Zhang, Y., Zhao, T., Wu, L., Zhao, Y. et
- 884 al. (2017). WIP1 Phosphatase Plays a Critical Neuroprotective Role in Brain Injury Induced by
- 885 High-Altitude Hypoxic Inflammation. Neurosci. Bull. 33, 292-298.
- ⁸⁸⁶66. Andreone, B.J., Przybyla, L., Llapashtica, C., Rana, A., Davis, S.S., van Lengerich, B., Lin,
- 887 K., Shi, J., Mei, Y., Astarita, G. et al. (2020). Alzheimer's-associated PLCγ2 is a signaling node
- 888 required for both TREM2 function and the inflammatory response in human microglia. Nat.
- 889 Neurosci. 23, 927-938.
- ⁸⁹⁰67. Poh, L., Kang, S.W., Baik, S.H., Ng, G.Y.Q., She, D.T., Balaganapathy, P., Dheen, S.T.,
- 891 Magnus, T., Gelderblom, M., Sobey, C.G. et al. (2019). Evidence that NLRC4 inflammasome
- 892 mediates apoptotic and pyroptotic microglial death following ischemic stroke. Brain Behav.
- 893 Immun. 75, 34-47.

- ⁸⁹⁴68. Bergsbaken, T., Fink, S.L., Cookson, B.T. (2009). Pyroptosis: host cell death and
- 895 inflammation. Nat. Rev. Microbiol. 7, 99-109.
- 896 69. Freeman, L., Guo, H., David, C.N., Brickey, W.J., Jha, S., Ting, J.P. (2017). NLR members
- 897 NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. J. Exp.
- 898 Med. 214, 1351-1370.
- ⁸⁹⁹70. DePaula-Silva, A.B., Gorbea, C., Doty, D.J., Libbey, J.E., Sanchez, J.M.S., Hanak, T.J.,
- 900 Cazalla, D., Fujinami, R.S. (2019). Differential transcriptional profiles identify microglial- and
- 901 macrophage-specific gene markers expressed during virus-induced neuroinflammation. J.
- 902 Neuroinflammation 16, 152-019-1545-x.
- ⁹⁰³71. Zhao, D., Mokhtari, R., Pedrosa, E., Birnbaum, R., Zheng, D., Lachman, H.M. (2017).
- ⁹⁰⁴Transcriptome analysis of microglia in a mouse model of Rett syndrome: differential expression
- 905 of genes associated with microglia/macrophage activation and cellular stress. Mol. Autism 8, 17-906 017-0134-z. eCollection 2017.
- 907 72. Jeong J, Li Y, Roche KW. CaMKII Phosphorylation Regulates Synaptic Enrichment of
- 908 Shank3. eNeuro. 2021 Feb 9:ENEURO.0481-20.2021. doi: 10.1523/ENEURO.0481-20.2021.
- 909 73. Lee, K., Vyas, Y., Garner, C.C., Montgomery, J.M. (2019). Autism-associated Shank3
- 910 mutations alter mGluR expression and mGluR-dependent but not NMDA receptor-dependent
- 911 long-term depression. Synapse 73, e22097.
- 912 74. Duffney, L.J., Wei, J., Cheng, J., Liu, W., Smith, K.R., Kittler, J.T., Yan, Z. (2013). Shank3
- 913 deficiency induces NMDA receptor hypofunction via an actin-dependent mechanism. J.
- 914 Neurosci. 33, 15767-15778.

- 915 75. Raynaud, F., Janossy, A., Dahl, J., Bertaso, F., Perroy, J., Varrault, A., Vidal, M., Worley,
- 916 P.F., Boeckers, T.M., Bockaert, J. et al. (2013). Shank3-Rich2 interaction regulates AMPA
- 917 receptor recycling and synaptic long-term potentiation. J. Neurosci. 33, 9699-9715.
- 918 76. Alexandrov, P.N., Zhao, Y., Jaber, V., Cong, L., Lukiw, W.J. (2017). Deficits in the Proline-
- 919 Rich Synapse-Associated Shank3 Protein in Multiple Neuropsychiatric Disorders. Front. Neurol. 920 8, 670.
- 921 77. Redin, C., Gerard, B., Lauer, J., Herenger, Y., Muller, J., Quartier, A., Masurel-Paulet, A.,
- 922 Willems, M., Lesca, G., El-Chehadeh, S. et al. (2014). Efficient strategy for the molecular
- 923 diagnosis of intellectual disability using targeted high-throughput sequencing. J. Med. Genet.
- ⁹²⁴78. Leblond, C.S., Nava, C., Polge, A., Gauthier, J., Huguet, G., Lumbroso, S., Giuliano, F.,
- 925 Stordeur, C., Depienne, C., Mouzat, K. et al. (2014). Meta-analysis of SHANK Mutations in
- 926 Autism Spectrum Disorders: a gradient of severity in cognitive impairments. PLoS Genet. 10, 927 e1004580.
- 928 79. Guilmatre, A., Huguet, G., Delorme, R., Bourgeron, T. (2014). The emerging role of SHANK 929 genes in neuropsychiatric disorders. Dev. Neurobiol. 74, 113-122.
- ⁹³⁰80. Bey, A.L., Gorman, M.P., Gallentine, W., Kohlenberg, T.M., Frankovich, J., Jiang, Y.H., Van
- 931 Haren, K. (2020). Subacute Neuropsychiatric Syndrome in Girls With SHANK3 Mutations
- 932 Responds to Immunomodulation. Pediatrics 145, e20191490. doi: 10.1542/peds.2019-1490.
- ⁹³³81. Kohlenberg, T.M., Trelles, M.P., McLarney, B., Betancur,C., Thurm, A., Kolevzon, A.
- ⁹³⁴(2020).Psychiatric illness and regression in individuals with Phelan-McDermid syndrome. J
- 935 Neurodev Disord Feb 12;12(1):7.
- ⁹³⁶82. Berryer, M.H., Hamdan, F.F., Klitten, L.L., Moller, R.S., Carmant, L., Schwartzentruber, J.,
- 937 Patry, L., Dobrzeniecka, S., Rochefort, D., Neugnot-Cerioli, M. et al. (2013). Mutations in

- 938 SYNGAP1 cause intellectual disability, autism, and a specific form of epilepsy by inducing
- 939 haploinsufficiency. Hum. Mutat. 34, 385-394.
- 940 83. Santos-Gómez, A., Miguez-Cabello, F., García-Recio, A., Locubiche, S., García-Díaz, R.,
- 941 Soto, V., Guerrero-López, R., Juliá-Palacios, N., Ciruela, F., García-Cazorla, À. et al. (2020).
- 942 Disease-associated GRIN protein truncating variants trigger NMDA receptor loss-of-function.
- 943 Hum. Mol. Genet.
- ⁹⁴⁴84. Myers, S.J., Yuan, H., Kang, J.Q., Tan, F.C.K., Traynelis, S.F., Low, C.M. (2019). Distinct
- 945 roles of GRIN2A and GRIN2B variants in neurological conditions. F1000Res 8,
- ⁹⁴⁶10.12688/f1000research.18949.1. eCollection 2019.
- 947 85. Strehlow, V., Heyne, H.O., Vlaskamp, D.R.M., Marwick, K.F.M., Rudolf, G., de Bellescize,
- 948 J., Biskup, S., Brilstra, E.H., Brouwer, O.F., Callenbach, P.M.C. et al. (2019). GRIN2A-related
- 949 disorders: genotype and functional consequence predict phenotype. Brain 142, 80-92.
- ⁹⁵⁰86. Liao, X., Li, Y. (2020). Genetic associations between voltage-gated calcium channels and
- 951 autism spectrum disorder: a systematic review. Mol. Brain 13, 96-020-00634-0.
- ⁹⁵²87. Araki, Y., Hong, I., Gamache, T.R., Ju, S., Collado-Torres, L., Shin, J.H., Huganir, R.L.
- ⁹⁵³(2020). SynGAP isoforms differentially regulate synaptic plasticity and dendritic development.
- 954 Elife 9, 10.7554/eLife.56273.
- ⁹⁵⁵88. Li, J., Zhang, J., Tang, W., Mizu, R.K., Kusumoto, H., XiangWei, W., Xu, Y., Chen, W.,
- 956 Amin, J.B., Hu, C. et al. (2019). De novo GRIN variants in NMDA receptor M2 channel pore-
- 957 forming loop are associated with neurological diseases. Hum. Mutat. 40, 2393-2413.
- ⁹⁵⁸89. Ryan, T.J., Kopanitsa, M.V., Indersmitten, T., Nithianantharajah, J., Afinowi, N.O., Pettit, C.,
- 959 Stanford, L.E., Sprengel, R., Saksida, L.M., Bussey, T.J. et al. (2013). Evolution of GluN2A/B

960 cytoplasmic domains diversified vertebrate synaptic plasticity and behavior. Nat. Neurosci. 16, ⁹⁶¹25-32.

- ⁹⁶²90. Seo, B.A., Lee, J.H., Kim, H.M., Kang, M.G. (2018). Neuronal calcium channel α(1) subunit
- 963 interacts with AMPA receptor, increasing its cell surface localisation. Biochem. Biophys. Res.
- 964 Commun. 498, 402-408.
- ⁹⁶⁵91. SnowdenJ.A., Badoglio, M., Alexander,T. (2019). The rise of autologous HCT for
- 966 autoimmune diseases: what is behind it and what does it mean for the future of treatment? An
- 967 update on behalf of the EBMT Autoimmune Diseases Working Party. Expert Rev Clin Immunol.
- 968 2019 Oct;15(10):981-985.
- ⁹⁶⁹92. Kristinsson, S.Y., Landgren, O., Sjöberg, J., Turesson, I., Björkholm, M., Goldin, L.R. (2009).
- 970 Autoimmunity and risk for Hodgkin's lymphoma by subtype. Haematologica 94, 1468-1469.
- ⁹⁷¹93. Urayama, K.Y., Jarrett, R.F., Hjalgrim, H., Diepstra, A., Kamatani, Y., Chabrier, A.,
- 972 Gaborieau, V., Boland, A., Nieters, A., Becker, N. et al. (2012). Genome-wide association study
- 973 of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J. Natl.
- 974 Cancer Inst. 104, 240-253.
- ⁹⁷⁵94. Nakayama, S., Yokote, T., Hiraoka, N., Nishiwaki, U., Hanafusa, T., Nishimura, Y., Tsuji, M.
- 976 (2016). Role of mast cells in fibrosis of classical Hodgkin lymphoma. Int. J. Immunopathol.
- 977 Pharmacol. 29, 603-611.
- ⁹⁷⁸95. Nanda, H., Ponnusamy, N., Odumpatta, R., Jeyakanthan, J., Mohanapriya, A. (2020).
- ⁹⁷⁹Exploring genetic targets of psoriasis using genome wide association studies (GWAS) for drug
- 980 repurposing. 3 Biotech 10, 43-019-2038-4. Epub 2020 Jan 10.
- 981 96. Li, B., Huang, L., Lv, P., Li, X., Liu, G., Chen, Y., Wang, Z., Qian, X., Shen, Y., Li, Y. et al.
- 982 (2020). The role of Th17 cells in psoriasis. Immunol. Res. 68, 296-309.

- 983 97. Wang, T., Hoekzema, K., Vecchio, D., Wu, H., Sulovari, A., Coe, B.P., Gillentine, M.A.,
- 984 Wilfert, A.B., Perez-Jurado, L.A., Kvarnung, M. et al. (2020). Large-scale targeted sequencing
- 985 identifies risk genes for neurodevelopmental disorders. Nat. Commun. 11, 4932-020-18723-y.
- 986 98. Li, X., Guo, S., Liu, K., Zhang, C., Chang, H., Yang, W., Rong, S., Hu, Q., Cui, J., Wang, F.
- 987 et al. (2020). GABRG2 Deletion Linked to Genetic Epilepsy with Febrile Seizures Plus Affects
- 988 the Expression of GABA(A) Receptor Subunits and Other Genes at Different Temperatures.
- 989 Neuroscience 438, 116-136.
- ⁹⁹⁰99. Jiang, Y.L., Song, C., Wang, Y., Zhao, J., Yang, F., Gao, Q., Leng, X., Man, Y., Jiang, W.
- 991 (2020). Clinical Utility of Exome Sequencing and Reinterpreting Genetic Test Results in
- 992 Children and Adults With Epilepsy. Front. Genet. 11, 591434.
- 993 100. Li, J., Liu, Y., Li, Q., Huang, X., Zhou, D., Xu, H., Zhao, F., Mi, X., Wang, R., Jia, F. et al.
- ⁹⁹⁴(2020). Mutation in ε-Sarcoglycan Induces a Myoclonus-Dystonia Syndrome-Like Movement 995 Disorder in Mice. Neurosci. Bull.
- 996 101. Yankova, G., Bogomyakova, O., Tulupov, A. (2021). The glymphatic system and
- 997 meningeal lymphatics of the brain: new understanding of brain clearance. Rev. Neurosci.
- 998 102. Manouchehrian, O., Ramos, M., Bachiller, S., Lundgaard, I., Deierborg, T. (2021). Acute
- 999 systemic LPS-exposure impairs perivascular CSF distribution in mice. J. Neuroinflammation 18, ¹⁰⁰⁰34-021-02082-6.
- 1001 103. Nedergaard, M., Goldman, S.A. (2020). Glymphatic failure as a final common pathway to 1002 dementia. Science 370, 50-56.
- 1003 104. LeDoux, M.S. (2020). Population Prevalence of Deleterious SGCE Variants. Tremor Other 1004 Hyperkinet Mov. (N. Y) 10, 50.

- ¹⁰⁰⁵105. Delgado-Alvarado, M., Matilla-Dueñas, A., Altadill-Bermejo, A., Setién, S., Misiego-Peral,
- 1006 M., Sánchez-de la Torre, J.R., Corral-Juan, M., Riancho, J. (2020). A novel SGCE variant is
- 1007 associated with myoclonus-dystonia with phenotypic variability. Neurol. Sci. 41, 3779-3781.
- ¹⁰⁰⁸106. Peall, K.J., Smith, D.J., Kurian, M.A., Wardle, M., Waite, A.J., Hedderly, T., Lin, J.P.,
- 1009 Smith, M., Whone, A., Pall, H. et al. (2013). SGCE mutations cause psychiatric disorders:
- 1010 clinical and genetic characterization. Brain 136, 294-303.
- 1011 107. Fernández-Marmiesse, A., Kusumoto, H., Rekarte, S., Roca, I., Zhang, J., Myers, S.J.,
- ¹⁰¹²Traynelis, S.F., Couce, M.L., Gutierrez-Solana, L., Yuan, H. (2018). A novel missense mutation
- 1013 in GRIN2A causes a nonepileptic neurodevelopmental disorder. Mov. Disord. 33, 992-999.
- 1014 108. Coco□, R., Raicu, F., Băjenaru, O.L., Olaru, I., Dumitrescu, L., Popescu, B.O. (2020).
- 1015 CACNA1B gene variants in adult-onset isolated focal dystonia. Neurol. Sci.
- ¹⁰¹⁶109. Klitten, L.L., Møller, R.S., Nikanorova, M., Silahtaroglu, A., Hjalgrim, H., Tommerup, N.
- ¹⁰¹⁷(2011). A balanced translocation disrupts SYNGAP1 in a patient with intellectual disability,
- 1018 speech impairment, and epilepsy with myoclonic absences (EMA). Epilepsia 52, e190-3.
- ¹⁰¹⁹110. von Stülpnagel, C., Hartlieb, T., Borggräfe, I., Coppola, A., Gennaro, E., Eschermann, K.,
- 1020 Kiwull, L., Kluger, F., Krois, I., Møller, R.S. et al. (2019). Chewing induced reflex seizures
- ¹⁰²¹("eating epilepsy") and eye closure sensitivity as a common feature in pediatric patients with
- ¹⁰²²SYNGAP1 mutations: Review of literature and report of 8 cases. Seizure 65, 131-137.
- ¹⁰²³111. Manthiram, K., Zhou, Q., Aksentijevich, I., Kastner, D.L. (2017). The monogenic
- 1024 autoinflammatory diseases define new pathways in human innate immunity and inflammation.
- 1025 Nat. Immunol. 18, 832-842.
- ¹⁰²⁶112. Taniguchi, K., Karin, M. (2018). NF-κB, inflammation, immunity and cancer: coming of age.
- 1027 Nat. Rev. Immunol. 18, 309-324.

- ¹⁰²⁸113. Liu, T., Zhang, L., Joo, D., Sun, S.C. (2017). NF-κB signaling in inflammation. Signal.
- 1029 Transduct Target Ther. 2, 17023.
- 1030 114. Comeau, K., Paradism P., Schiffrin, E.L. (2000). Human and murine memory gammadelta
- 1031 T cells: Evidence for acquired immune memory in bacterial and viral infections and
- ¹⁰³²autoimmunity. Cell Immunol. Nov;357:104217. doi: 10.1016/j.cellimm.2020.104217. Epub 2020
- 1033 Sep 16.
- ¹⁰³⁴115. Li, Y., Zhang, Y., Zeng, X. (2021). γδ T Cells Participating in Nervous Systems: A Story of
- 1035 Jekyll and Hyde. Front Immunol. Mar 31; 12:656097. Published online 2021 Mar 31. doi:
- ¹⁰³⁶10.3389/fimmu.2021.656097
- ¹⁰³⁷116. Alves de Lima, K., Rustenhoven, J., Da Mesquita, S., Wall, M., Salvador, A.F., Smirnov, I.,

¹⁰³⁸Cebinelli, G.M., Mamuladze, T., Baker, W., Papadopoulos, Z, et al. (2020). Meningeal γδ T cells 1039 regulate anxiety-like behavior via IL-17a signaling in neurons. Nat Immunol. Nov;21(11):1421-1040 1429.

- 1041 117. Korzh, V. (2018). Development of brain ventricular system. Cell Mol,. Life Sci. 75, 375-383.
- ¹⁰⁴²118. Javed, K., Reddy, V., Lui, F. (2021). Neuroanatomy, Choroid Plexus. In StatPearls,
- 1043 Anonymous (Treasure Island (FL): StatPearls Publishing LLC).
- ¹⁰⁴⁴119. Hubert, V., Dumot, C., Ong, E., Amaz, C., Canet-Soulas, E., Chauveau, F., Wiart, M.
- ¹⁰⁴⁵(2019). MRI coupled with clinically-applicable iron oxide nanoparticles reveals choroid plexus
- 1046 involvement in a murine model of neuroinflammation. Sci. Rep. 9, 10046-019-46566-1.
- ¹⁰⁴⁷120. Prinz, M., Masuda, T., Wheeler, M.A., Quintana, F.J. (2021). Microglia and Central
- 1048 Nervous System-Associated Macrophages-From Origin to Disease Modulation. Annu. Rev.
- 1049 Immunol.

- 1050 121. Huang, X., Hussain, B., Chang, J. (2021). Peripheral inflammation and blood-brain barrier
- 1051 disruption: effects and mechanisms. CNS Neurosci. Ther. 27, 36-47.
- ¹⁰⁵²122. Earl, R.K., Turner, T.N., Mefford, H.C., Hudac, C.M., Gerdts, J., Eichler, E.E., Bernier, R.A.
- ¹⁰⁵³(2017). Clinical phenotype of ASD-associated DYRK1A haploinsufficiency. Mol. Autism 8, 54-
- ¹⁰⁵⁴017-0173-5. eCollection 2017.
- ¹⁰⁵⁵123. O'Roak, B.J., Vives, L., Fu, W., Egertson, J.D., Stanaway, I.B., Phelps, I.G., Carvill, G.,
- 1056 Kumar, A., Lee, C., Ankenman, K. et al. (2012). Multiplex targeted sequencing identifies
- 1057 recurrently mutated genes in autism spectrum disorders. Science 338, 1619-1622.
- ¹⁰⁵⁸124. Dang, T., Duan, W.Y., Yu, B., Tong, D.L., Cheng, C., Zhang, Y.F., Wu, W., Ye, K., Zhang,
- ¹⁰⁵⁹W.X., Wu, M. et al. (2018). Autism-associated Dyrk1a truncation mutants impair neuronal
- 1060 dendritic and spine growth and interfere with postnatal cortical development. Mol. Psychiatry 23, 1061 747-758.
- 1062 125. Cerboni, S., Gehrmann, U., Preite, S., Mitra, S. (2020). Cytokine-regulated Th17 plasticity 1063 in human health and diseases. Immunology.
- ¹⁰⁶⁴126. Cerboni, S., Gehrmann, U., Preite, S., Mitra, S. (2020). Cytokine-regulated Th17 plasticity
- 1065 in human health and diseases. Immunology.
- 1066 127. Zhang, R., Miao, J., Zhu, P. (2020). Regulatory T cell heterogeneity and therapy in
- 1067 autoimmune diseases. Autoimmun. Rev., 102715.

1069 the luxury model. Cell. Immunol. 358, 104220.

- 1068 128. Rosado-Sánchez, I., Levings, M.K. (2020). Building a CAR-Treg: Going from the basic to
- ¹⁰⁷⁰129. Khor, B., Gagnon, J.D., Goel, G., Roche, M.I., Conway, K.L., Tran, K., Aldrich, L.N.,
- 1071 Sundberg, T.B., Paterson, A.M., Mordecai, S. et al. (2015). The kinase DYRK1A reciprocally
- 1072 regulates the differentiation of Th17 and regulatory T cells. Elife 4, 10.7554/eLife.05920.

- ¹⁰⁷³130. Platt, M.P., Bolding, K.A., Wayne, C.R., Chaudhry, S., Cutforth, T., Franks, K.M., Agalliu,
- 1074 D. (2020). Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of
- 1075 postinfectious autoimmune encephalitis. Proc. Natl. Acad. Sci. U. S. A. 117, 6708-6716.
- 1076 131. Cutforth, T., DeMille, M.M., Agalliu, I., Agalliu, D. (2016). CNS autoimmune disease after
- 1077 Streptococcus pyogenes infections: animal models, cellular mechanisms and genetic factors.
- 1078 Future Neurol. 11, 63-76.
- ¹⁰⁷⁹132. Dileepan, T., Smith, E.D., Knowland, D., Hsu, M., Platt, M., Bittner-Eddy, P., Cohen, B.,
- 1080 Southern, P., Latimer, E., Harley, E. et al. (2016). Group A Streptococcus intranasal infection
- 1081 promotes CNS infiltration by streptococcal-specific Th17 cells. J. Clin. Invest. 126, 303-317.
- ¹⁰⁸²133. Choi, D.W., Na, W., Kabir, M.H., Yi, E., Kwon, S., Yeom, J., Ahn, J.W., Choi, H.H., Lee, Y.,
- 1083 Seo, K.W. et al. (2013). WIP1, a homeostatic regulator of the DNA damage response, is

1084 targeted by HIPK2 for phosphorylation and degradation. Mol. Cell 51, 374-385.

- ¹⁰⁸⁵134. Xu, L., Fang, H., Xu, D., Wang, G. (2020). HIPK2 sustains inflammatory cytokine
- 1086 production by promoting endoplasmic reticulum stress in macrophages. Exp. Ther. Med. 20, 1087 171.
- 1088 135. Li, R., Shang, J., Zhou, W., Jiang, L., Xie, D., Tu, G. (2018). Overexpression of HIPK2

1089 attenuates spinal cord injury in rats by modulating apoptosis, oxidative stress, and inflammation. 1090 Biomed. Pharmacother. 103, 127-134.

- 1091 136. Lewin, A.B., Storch, E.A., Murphy, T.K. (2011). Pediatric autoimmune neuropsychiatric
- 1092 disorders associated with Streptococcus in identical siblings. J. Child Adolesc.
- 1093 Psychopharmacol. 21, 177-182.
- ¹⁰⁹⁴137. Gan, L., O'Hanlon, T.P., Gordon, A.S., Rider, L.G., Miller, F.W., Burbelo, P.D. (2014).
- ¹⁰⁹⁵Twins discordant for myositis and systemic lupus erythematosus show markedly enriched

- 1096 autoantibodies in the affected twin supporting environmental influences in pathogenesis. BMC 1097 Musculoskelet. Disord. 15, 67-2474-15-67.
- ¹⁰⁹⁸138. Moretti, R., Pansiot, J., Bettati, D., Strazielle, N., Ghersi-Egea, J.F., Damante, G., Fleiss,
- 1099 B., Titomanlio, L., Gressens, P. (2015). Blood-brain barrier dysfunction in disorders of the
- 1100 developing brain. Front. Neurosci. 9, 40.
- 1101 139. Huett, A., Leong, J.M., Podolsky, D.K., Xavier, R.J. (2009). The cytoskeletal scaffold
- 1102 Shank3 is recruited to pathogen-induced actin rearrangements. Exp. Cell Res. 315, 2001-2011.
- ¹¹⁰³140. Zhen, H., Zhao, L., Ling, Z., Kuo, L., Xue, X., Feng, J. (2018). Wip1 regulates blood-brain
- 1104 barrier function and neuro-inflammation induced by lipopolysaccharide via the sonic hedgehog
- 1105 signaling signaling pathway. Mol. Immunol. 93, 31-37.
- 1106 141. Goasdoué, K., Miller, S.M., Colditz, P.B., Björkman, S.T. (2017). Review: The blood-brain
- 1107 barrier; protecting the developing fetal brain. Placenta 54, 111-116.
- ¹¹⁰⁸142. Lombardo, M.V., Moon, H.M., Su, J., Palmer, T.D., Courchesne, E., Pramparo, T. (2018).
- ¹¹⁰⁹Maternal immune activation dysregulation of the fetal brain transcriptome and relevance to the
- 1110 pathophysiology of autism spectrum disorder. Mol. Psychiatry 23, 1001-1013.
- 1111 143. Spann, M.N., Monk, C., Scheinost, D., Peterson, B.S. (2018). Maternal Immune Activation
- 1112 During the Third Trimester Is Associated with Neonatal Functional Connectivity of the Salience
- 1113 Network and Fetal to Toddler Behavior. J. Neurosci. 38, 2877-2886.
- 1114 144. Ducharme, G., Lowe, G.C., Goutagny, R., Williams, S. (2012). Early alterations in
- 1115 hippocampal circuitry and theta rhythm generation in a mouse model of prenatal infection:
- 1116 implications for schizophrenia. PLoS One 7, e29754.

- ¹¹¹⁷145. Arnold, S.E., Franz, B.R., Gur, R.C., Gur, R.E., Shapiro, R.M., Moberg, P.J., Trojanowski,
- 1118 J.Q. (1995). Smaller neuron size in schizophrenia in hippocampal subfields that mediate
- 1119 cortical-hippocampal interactions. Am. J. Psychiatry 152, 738-748.
- 1120 146. Benes, F.M. (2011). Regulation of cell cycle and DNA repair in post-mitotic GABA neurons
- 1121 in psychotic disorders. Neuropharmacology 60, 1232-1242.
- ¹¹²²147. Benes, F.M., Lim, B., Matzilevich, D., Subburaju, S., Walsh, J.P. (2008). Circuitry-based
- 1123 gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus
- ¹¹²⁴bipolars. Proc. Natl. Acad. Sci. U. S. A. 105, 20935-20940.
- ¹¹²⁵148. Benes, F.M., Lim, B., Matzilevich, D., Walsh, J.P., Subburaju, S., Minns, M. (2007).
- 1126 Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc.
- 1127 Natl. Acad. Sci. U. S. A. 104, 10164-10169.
- 1128 149. Smith, S.E., Li, J., Garbett, K., Mirnics, K., Patterson, P.H. (2007). Maternal immune
- 1129 activation alters fetal brain development through interleukin-6. J. Neurosci. 27, 10695-10702.
- ¹¹³⁰150. Bauman, M.D., Iosif, A.M., Smith, S.E., Bregere, C., Amaral, D.G., Patterson, P.H. (2014).
- 1131 Activation of the maternal immune system during pregnancy alters behavioral development of
- 1132 rhesus monkey offspring. Biol. Psychiatry 75, 332-341.
- 1133 151. Meyer, U., Feldon, J., Fatemi, S.H. (2009). In-vivo rodent models for the experimental
- 1134 investigation of prenatal immune activation effects in neurodevelopmental brain disorders.
- 1135 Neurosci. Biobehav. Rev. 33, 1061-1079.
- ¹¹³⁶152. Oskvig, D.B., Elkahloun, A.G., Johnson, K.R., Phillips, T.M., Herkenham, M. (2012).
- 1137 Maternal immune activation by LPS selectively alters specific gene expression profiles of
- 1138 interneuron migration and oxidative stress in the fetus without triggering a fetal immune
- 1139 response. Brain Behav. Immun. 26, 623-634.

- 1140 153. Lünemann, J.D., Nimmerjahn, F., Dalakas, M.C. (2015). Intravenous immunoglobulin in
- 1141 neurology--mode of action and clinical efficacy. Nat. Rev. Neurol. 11, 80-89.
- 1142 154. Norris, P.A.A., Kaur, G., Lazarus, A.H. (2020). New insights into IVIg mechanisms and
- 1143 alternatives in autoimmune and inflammatory diseases. Curr. Opin. Hematol. 27, 392-398.
- ¹¹⁴⁴155. Bayry, J., Thirion, M., Misra, N., Thorenoor, N., Delignat, S., Lacroix-Desmazes, S., Bellon,
- 1145 B., Kaveri, S., Kazatchkine, M.D. (2003). Mechanisms of action of intravenous immunoglobulin
- 1146 in autoimmune and inflammatory diseases. Neurol. Sci. 24 Suppl 4, S217-21.
- ¹¹⁴⁷156. Poetsch, V., Neuhaus, W., Noe, C.R. (2010). Serum-derived immunoglobulins neutralize
- 1148 adverse effects of amyloid-beta peptide on the integrity of a blood-brain barrier in vitro model. J.
- 1149 Alzheimers Dis. 21, 303-314.
- 1150 157. Jones, H.F., Ho, A.C.C., Sharma, S., Mohammad, S.S., Kothur, K., Patel, S., Brilot, F.,
- 1151 Guastella, A.J., Dale, R.C., Immune-Neurodevelopment (Imm-Nd) Study Group. (2019).
- 1152 Maternal thyroid autoimmunity associated with acute-onset neuropsychiatric disorders and
- 1153 global regression in offspring. Dev. Med. Child Neurol. 61, 984-988.
- ¹¹⁵⁴158. Lin, J.R., Cai, Y., Zhang, Q., Zhang, W., Nogales-Cadenas, R., Zhang, Z.D. (2016).
- 1155 Integrated Post-GWAS Analysis Sheds New Light on the Disease Mechanisms of
- 1156 Schizophrenia. Genetics 204, 1587-1600.
- ¹¹⁵⁷159. García-Cuesta, E.M., Santiago, C.A., Vallejo-Díaz, J., Juarranz, Y., Rodríguez-Frade, J.M.,
- 1158 Mellado, M. (2019). The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases.
- 1159 Front. Endocrinol. (Lausanne) 10, 585.
- ¹¹⁶⁰160. Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K.,
- 1161 Presumey, J., Baum, M., Van Doren, V. et al. (2016). Schizophrenia risk from complex variation
- 1162 of complement component 4. Nature 530, 177-183.

- 1163 161. Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological
- 1164 insights from 108 schizophrenia-associated genetic loci. Nature 511, 421-427.
- 1165 162. Hafizi, S., Tabatabaei, D., Lai, M.C. (2019). Review of Clinical Studies Targeting
- 1166 Inflammatory Pathways for Individuals With Autism. Front. Psychiatry. 10, 849.
- ¹¹⁶⁷163. Atladóttir, H.O., Pedersen, M.G., Thorsen, P., Mortensen, P.B., Deleuran, B., Eaton, W.W.,
- 1168 Parner, E.T. (2009). Association of family history of autoimmune diseases and autism spectrum
- 1169 disorders. Pediatrics 124, 687-694.
- ¹¹⁷⁰164. Lyall, K., Ames, J.L., Pearl, M., Traglia, M., Weiss, L.A., Windham, G.C., Kharrazi, M.,
- 1171 Yoshida, C.K., Yolken, R., Volk, H.E. et al. (2021). A profile and review of findings from the
- ¹¹⁷²Early Markers for Autism study: unique contributions from a population-based case-control
- 1173 study in California. Mol. Autism 12, 24-021-00429-7.
- 1174 165. Dantzer, R. (2018). Neuroimmune Interactions: From the Brain to the Immune System and 1175 Vice Versa. Physiol. Rev. 98, 477-504.
- ¹¹⁷⁶166. Quagliariello, A., Del Chierico, F., Russo, A., Reddel, S., Conte, G., Lopetuso, L.R., Ianiro,
- 1177 G., Dallapiccola, B., Cardona, F., Gasbarrini, A. et al. (2018). Gut Microbiota Profiling and Gut-
- 1178 Brain Crosstalk in Children Affected by Pediatric Acute-Onset Neuropsychiatric Syndrome and
- 1179 Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections.
- 1180 Front. Microbiol. 9, 675.
- ¹¹⁸¹167. Pellegrini, C., Antonioli, L., Calderone, V., Colucci, R., Fornai, M., Blandizzi, C. (2020).
- 1182 Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of
- 1183 microbiota-gut-brain communications? Prog. Neurobiol. 191, 101806.
- ¹¹⁸⁴168. Loffredo, L., Spalice, A., Salvatori, F., De Castro, G., Guido, C.A., Zicari, A.M., Ciacci, P.,
- 1185 Battaglia, S., Brindisi, G., Ettorre, E. et al. (2020). Oxidative stress and gut-derived

- ¹¹⁸⁶lipopolysaccharides in children affected by paediatric autoimmune neuropsychiatric disorders
- 1187 associated with streptococcal infections. BMC Pediatr. 20, 127-020-02026-8.
- 1188 169. Sauer, A.K., Bockmann, J., Steinestel, K., Boeckers, T.M., Grabrucker, A.M. (2019).
- 1189 Altered Intestinal Morphology and Microbiota Composition in the Autism Spectrum Disorders
- ¹¹⁹⁰Associated SHANK3 Mouse Model. Int. J. Mol. Sci. 20, 2134. doi: 10.3390/ijms20092134.
- 1191 170. Wei, S.C., Yang-Yen, H.F., Tsao, P.N., Weng, M.T., Tung, C.C., Yu, L.C.H., Lai, L.C.,
- 1192 Hsiao, J.H., Chuang, E.Y., Shun, C.T. et al. (2017). SHANK3 Regulates Intestinal Barrier
- 1193 Function Through Modulating ZO-1 Expression Through the PKCε-dependent Pathway.
- 1194 Inflamm. Bowel Dis. 23, 1730-1740.
- ¹¹⁹⁵171. Rodrigues, F., Hentgen, V., Bachmeyer, C., Kone-Paut, I., Belot, A., Grateau, G.,
- 1196 Sarrabay, G., Georgin-Lavialle, S. (2018). [NLRC4 associated autoinflammatory diseases: A
- 1197 systematic review of the current literature]. Rev Med Interne. 2018 Apr;39(4):279-286.2
- 1198 Opipari, A., Franchi, L., Role of inflammasomes in intestinal inflammation and Crohn's disease.
- ¹¹⁹⁹(2015). Inflamm Bowel Dis. Jan;21(1):173-81.
- 1200 173. Tse, J.K.Y. (2017). Gut Microbiota, Nitric Oxide, and Microglia as Prerequisites for
- 1201 Neurodegenerative Disorders. ACS Chem. Neurosci. 8, 1438-1447.
- ¹²⁰²174. Esposito, G., Sarnelli, G., Capoccia, E., Cirillo, C., Pesce, M., Lu, J., Calì, G., Cuomo, R.,
- 1203 Steardo, L. (2016). Autologous transplantation of intestine-isolated glia cells improves
- 1204 neuropathology and restores cognitive deficits in β amyloid-induced neurodegeneration. Sci.
- 1205 Rep. 6, 22605.
- 1206 175. Niesler, B., Kuerten, S., Demir, I.E., Schäfer, K.H. (2021). Disorders of the enteric nervous 1207 system - a holistic view. Nat. Rev. Gastroenterol. Hepatol.

- ¹²³³**Figure 4.** Single cell RNA-seq expression pattern of each PANS candidate gene in mouse
- 1234 adolescent brains (mouse brain atlas; see Web Resources)
- 1235
- ¹²³⁶**Table Legends**
- ¹²³⁷**Table 1.** Diagnostic criteria for PANS/PANDAS adapted from reference 3 and NIMH (see Web
- 1238 Resources)
- ¹²³⁹**Table 2.** Summary of cases. Patient demographics, genetic variants, and brief clinical
- 1240 description. Bold type highlights cases with comorbid neurodevelopmental disorders, red type
- 1241 highlights those with a history of recurrent infections. For complete patient histories, see
- 1242 Supplemental Note: Case Reports. Abbreviations: pathogenic (P); likely pathogenic (LP); variant
- 1243 of unknown significance (VUS). To protect patient confidentiality, ages are not included. Each
- 1244 case showed the first signs of PANS before the age of 10.

PANS

I. Abrupt onset of obsessive-compulsive disorder or severely restricted food intake

II. Concurrent presence of additional neuropsychiatric symptoms with severe and acute onset from at least two of the following:

Anxiety

Emotional lability and/or depression

Irritability, aggression, and/or severely oppositional behaviors

Behavioral (developmental) regression

Deterioration in school performance (related to attention deficit/hyperactivity disorder [ADHD]-like symptoms,

memory deficits, cognitive changes Sensory or motor abnormalities

Somatic signs and symptoms, including sleep disturbances, enuresis, or urinary frequency

III. Symptoms are not better explained by a known neurologic or medical disorder

PANDAS

I. Abrupt onset of clinically significant obsessions, compulsions and/or tics

II. Association with Group A Streptococcal infection

III. Pre-pubertal onset

IV. Relapsing-remitting course

V. Association with other neuropsychiatric symptoms including:

Severe separation anxiety

Generalized anxiety

Motoric hyperactivity, abnormal movements, and a sense of restlessness

 Sensory abnormalities (sensitivity to light or sounds), distortions of visual perceptions, and occasionally, visual or auditory hallucinations

Difficulties concentrating, and loss of academic abilities, particularly in math and visual-spatial areas

Increased urinary frequency, or sense of urgency and/or a new onset of bed-wetting

Irritability, aggression, emotional lability.

Abrupt onset of depression with thoughts about suicide

Developmental regression, including temper tantrums, and handwriting deterioration

1246 Table 1

1248 Table 2012 Table 2012 Table 2012 Table 2012 Table 2013 Table 2013 Table 2013 Table 2013 Table 2013 Table 2
The contract of the contract o

<u> Andreas de la contrada de la p</u>

